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ABSTRACT OF THESIS

EFFECTS OF IN UTERO NICOTINE EXPOSURE ON IMMUNE CELL DISPOSITION
AFTER P. AERUGINOSA LUNG INFECTION
Current smoking cessation guidelines recommend nicotine replacement therapy
(NRT) to assist pregnant smokers to quit, but this is without strong evidence for
effectiveness and safety. Nicotine, the main addictive component of tobacco, is known to
exert physiological effects by binding to its receptor, the nicotinic acetylcholine receptor
(nAChR). Recent studies have identified the presence of nAChRs in non-neuronal cells,
and in macrophages, functional alteration upon stimulation with nicotine has been
documented.
To understand the impact of in utero nicotine exposure on various immune cell
disposition and function, we designed preliminary studies using an in vivo model of P.
aeruginosa infection. In this model, pregnant mice were exposed to nicotine and after
weaning, offspring were infected intra-tracheally and humanely killed 5 days later.
Nicotine-exposed mice had a greater weight reduction post-infection. This was
accompanied by a decreased number of neutrophil, resident macrophages, and B
lymphocytes in the lungs, while the number of B lymphocytes in the lymph nodes were
greater than that of the control group. In the lung lavage fluids, IL-6, MCP-1, and TNFα
concentrations were elevated in nicotine-exposed mice. In an in vitro system using bone
marrow-derived macrophages, a significantly reduced production of IFNγ was observed
in nicotine-exposed mice when cells were stimulated with LPS.
To characterize and compare gene expression in macrophages isolated from
neonates developmentally exposed to nicotine, we designed a clinical study to recruit
pregnant mothers who 1) did not smoke during pregnancy, 2) smoked throughout
pregnancy, or 3) used NRT during pregnancy. We found that successful RNA isolation
can be achieved from neonatal tracheal aspirate samples and cell number and reagent
volumes were important determinants of acceptable RNA quality and quantity.
Together, these preliminary findings demonstrate a possible alteration in immune
response as a result of in utero nicotine exposure and sets a groundwork for future
studies in identifying mechanisms underlying the impact of developmental nicotine
exposure.
KEYWORDS: Pregnancy, cigarette smoke, nicotine, non-neuronal cholinergic system,
macrophage, Pseudomonas aeruginosa
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Chapter 1. Introduction
A. Smoking and Pregnancy
a. Overview
Smoking is a significant contributor to several pathologies that lead to major
public health problems, such as cancer, cardiovascular disease, pulmonary disease, and
perinatal morbidity. It is the leading preventable cause of disease and death in the U.S.
across all age groups and genders (1, 2). Various methodologies, including nicotine
replacement therapy (NRT), have been studied and developed to aid smoking cessation
and minimize nicotine withdrawal.
Current practice guidelines recommend the use of NRT during pregnancy if
smoking cessation is not achieved with non-pharmacologic intervention alone (3). There
is general consensus that NRTs are safer than cigarette smoking during pregnancy due
to reduced exposure to the numerous toxins contained in cigarette smoke. Adverse
effects observed during pregnancy from smoking are also observed with nicotine
administration alone, signifying that NRT use in pregnancy should be extensively
examined. Their use is without sufficient data to support safety and effectiveness in
pregnant smokers, and importantly safety to the newborn has not been adequately
evaluated.
Nicotine, the main addictive component of tobacco, is known to exert
physiological effects by binding to its receptor, the nicotinic acetylcholine receptor
(nAChR). Recently, studies have identified the presence of nAChRs on non-neuronal
cells and have explored their role in normal cellular activities. The term non-neuronal
cholinergic system (NNCS) distinguishes these alternate functions from traditional
neuronal effects (4). The wide distribution of nAChR outside of the nervous system
expands the potential impact of nicotine, much of which is yet to be fully understood.
This contributes to another level of uncertainty regarding the safety and efficacy of NRT.
Moreover, exposure to nicotine during the critical period of fetal development could
induce abnormalities with regard to multiple aspects of cellular functions. This warrants
the pursuit of definitive answers to proper use of NRT during pregnancy.
The Barker Hypothesis, which was proposed based on the observed association
between birthweight and adult mortality outcomes, provides insight to the developmental
1

plasticity of the fetus and the importance of intrauterine conditions in shaping the proper
tone of fetal health, structurally and functionally, which subsequently affects
susceptibility to various diseases in adulthood (5). This concept highlights the critical role
of maternal cigarette use and its impact on observed perinatal outcomes.
In this section, the epidemiology of smoking will be discussed to understand the
prevalence of smoking, particularly in women during pregnancy, along with a review of
smoking cessation options to understand their place in use and to describe concerns
associated with current recommendations.

b. Epidemiology of tobacco use and smoking cessation guideline for
general population
Epidemiology of tobacco use
It is estimated that 37 million of the U.S. adults aged 18 years and older actively
smoke, and this behavior leads to the death of 480,000 people annually due to smoking
related illnesses. When translated into overall healthcare cost, including direct medical
cost and productivity loss, this equates to more than $300 billion per year (2).
Association between cigarette smoking and negative health consequences is well
established and highlighted by many in vitro, in vivo, and epidemiologic studies. The
majority of patients suffering from chronic diseases, including pulmonary disease,
cardiovascular disease, and cancer, have a strong link to a history of active and/or
passive smoking (Reviewed in 6). This data is not surprising since the inverse
relationship between cigarette smoking and positive health outcomes has been welldefined, and organizations encourage smoking cessation as the major preventative
measure for improving life expectancy (6, 7). However, complete cessation is difficult to
achieve due to various biological and physiological factors. For example, nicotine is
almost 100% bioavailable from an average cigarette and easily passes the blood-brain
barrier within 10-20 seconds due to its lipophilicity. Individuals with a long history of
smoking are accustomed to repetitive behavior of cigarette smoking and continuous
stimulation of the dependence-development pathway. Physiological effects mediated by
cigarette smoke are favorable towards inducing a reward response, which ultimately
lures the users to continue seeking this behavior. (8-10).
A concerning aspect of cigarette smoking is that ex-smokers and passive
smokers also have increased risk for similar diseases that may be irreversible. Ex2

smokers account for 50% of patients with lung disease diagnoses, and the rate of
diagnosis still exceeds that of never-smokers and persists even after 20 years of
abstinence (11). Progression of atherosclerosis plaque formation was associated more
with pack-years of smoking rather than current smoking status, suggesting cumulative
and permanent changes induced by smoking (12). A range of health problems observed
in passive smokers, such as lung and cardiovascular disease, are found in a similar
incidence to that of smokers, and the risk of certain diseases, such as female breast
cancer, allergic rhinitis, allergic dermatitis, and food allergy, may even be equally
elevated in active and passive smokers (13, 14). Passive smoking also impacts the
unborn fetus, as demonstrated by the detrimental effects observed in newborns exposed
to cigarette smoke in utero. Prematurity, low birth weight, and sudden infant death
syndrome are a few examples consistently reported to be linked to maternal smoking
(15). The topic of in utero exposure to tobacco will be discussed more in depth in the
following sections.
Smoking cessation guidelines
Various methodologies have been studied to reduce smoking prevalence,
promote smoking cessation, improve life expectancy, and reduce smoking-related
diseases (16). The United States Public Health Service (USPHS) established a clinical
practice guideline to help health professionals identify tobacco dependence and assist
patients with treatment strategies (3). The guideline emphasizes the importance of
behavioral counseling to understand patient’s readiness to quit, but also addresses the
use of pharmacotherapeutic intervention to assist with cessation. It strongly
recommends consistent intervention by clinicians and the use of a combination of
behavioral counseling and pharmacotherapy, which is more effective than either alone.
However, any intervention is more effective than no intervention and will significantly
lower healthcare cost, as treatment strategies for tobacco dependence are cost-effective
compared to other chronic diseases (3).
Currently, there are nicotine-based and non-nicotine based products approved by
the FDA as smoking cessation aids (8, 17). The most commonly used category is
nicotine containing products, known collectively as nicotine replacement therapy (NRT).
NRT is one of the first-line pharmacologic agents and is regarded as safe and effective
in the general population as it increases the quit rate by 50-70% (18-20). There are
multiple dosage forms available over the counter (gum, lozenge, and patch) and by
3

prescription (inhaler and nasal spray), which provides additional benefit of a tailored
approach based on patients’ need and willingness to adhere to therapy. NRT is
designed to slowly taper nicotine exposure and facilitate the transition from smoking to
cessation without experiencing withdrawal and craving. Depending on the history and
intensity of cigarette use, one can choose short-acting oral formulations or long-acting
transdermal formulation of NRT, or a combination of both, to mimic smoking behavior
(8). Although NRT use is associated with a variety of adverse events, those directly
associated to these products are limited to local reactions, such as skin irritation with
transdermal patch and mouth/throat soreness with oral administration. Systemic adverse
events, such as insomnia and sleep disturbances, may be related to smoking cessation
itself and not NRT use (21) (Table 1.1). The most serious adverse events reported were
cardiovascular symptoms, such as heart palpitations and chest pain, but a systematic
review and meta-analysis did not observe differences in the clinical incidence of
myocardial infarction or death in the NRT users. Also, the guideline concluded that NRT
is safe for patients with cardiovascular diseases (6, 21).
Other non-nicotine pharmacologic therapies include bupropion sustained release
(SR) and varenicline (3). Bupropion is an atypical antidepressant that inhibits reuptake of
dopamine and norepinephrine, ameliorating symptoms of reward, craving, and
withdrawal (23, 24). Smokers frequently suffer from or have a history of major
depression and they are less likely to achieve successful abstinence (25). Therefore,
bupropion may be an appealing option for smokers with major depression or who may
be at risk for developing depression upon quitting. It is also considered safe and
tolerable in selected “difficult-to-treat” populations, such as patients with COPD,
cardiovascular disease, or patients concerned for post-cessation weight gain. In one
study comparing the efficacy of bupropion SR for 12 weeks in 411 heavy smokers (≥ 15
cigarettes per day) with mild or moderate COPD, significantly increased cessation rates
were observed in those receiving bupropion SR compared to placebo. A significantly
higher number of patients in this group remained abstinent at the 6 month follow-up (26).
Another study validating the efficacy and safety of bupropion SR in 629 patients with
cardiovascular disease observed significantly increased cessation rates in the treatment
group after 12 months compared to placebo group. No clinically significant changes
were noted in blood pressure all throughout the study period (27). Combination of NRT
and bupropion led to a significant reduction in weight gain at 7 week post-cessation in a
study comparing bupropion SR, a nicotine patch, combination of bupropion SR and a
4

nicotine patch, and placebo in 893 patients (28). Adverse events associated with
bupropion use for depression are well reported, and similar events are expected when
used for smoking cessation, including dry mouth and insomnia. Special caution should
be utilized, however, in patients with risk factors for seizure, such as alcohol abuse and
concomitant use of antipsychotics and antidepressants known to lower seizure
threshold. Smokers with active seizure disorder or a history of seizures should not be
challenged with bupropion therapy (24).
Varenicline is a partial agonist of the α4β2 subtype of nAChR with a higher
affinity for the receptor than nicotine. With such properties, varenicline inhibits binding of
nicotine to the receptor while its binding only partially stimulates the receptor with
reduced effects. As a result, varenicline attentuates symptoms of withdrawal and
reduces craving (29). A pooled analysis evaluating the efficacy of varenicline versus
bupropion SR and placebo concluded greater continuous abstinence rates with
varenicline use (44.0% vs. 29.7% vs. 17.7% for varenicline, bupropion SR and placebo,
respectively) during weeks 9 to 12 of treatment, suggesting that varenicline may be more
effective than bupropion (30). Post-marketing surveillance data raised concerns for
possible neuropsychiatric adverse events, such as changes in behavior, depressed
mood, and suicidal ideation, leading to a boxed warning mandated by the FDA in 2009.
Subsequent analyses and large clinical trials found no difference in neuropsychiatric
events between varenicline and placebo groups, and the boxed warning was removed
by the FDA in December, 2016 (31). However, it is recommended that potential
neuropsychiatric adverse events are communicated with the patients and their
families/caregivers in detail, and to seek immediate assistance from a healthcare
provider if any of the described events occur while on therapy (29, 32, 33). Therefore,
although both NRT and non-NRT treatments are efficacious, the availability of NRT
products without a prescription and mild systemic adverse events reported provide
substantial advantages over the non-NRT products.
In summary, a large pool of evidence exists for smoking cessation aids, both
pharmacologic and non-pharmacologic, and various strategies can be adopted based on
patient-specific requirements and concerns as well as underlying medical conditions. It is
clear that any mode of cigarette smoke exposure, direct or indirect, results in increased
risks for acute and chronic diseases, and continuous encouragement and motivation are
the keys to successful and complete abstinence. However, the use of these therapies
during pregnancy requires additional consideration, as the complexity of the potential
5

impact on fetal development must be taken into account. The next section will begin to
address the use of NRT in this vulnerable population.

Medication

Available Dose

Duration

Side Effects

Nicotine gum

2mg, 4mg

12 weeks

Jaw ache, hiccups, dyspepsia

Nicotine lozenge

2mg, 4mg

12 weeks

Nausea, hiccups, heartburn

Nicotine transdermal
patch
Nicotine nasal spray

7mg, 14mg, 21mg over 24 hrs
10mg, 15mg, 25mg over 16 hrs
10mg/ml

10-12 weeks

Skin irritation, insomnia

3 months

Nasal irritation

Nicotine inhaler

10mg

6-12 weeks

Mouth and throat irritation,
cough

Bupropion SR

150mg

7-12 weeks

Insomnia, dry mouth

Varenicline

0.5mg, 1mg

12-24 weeks

Nausea, abnormal dreams

Table 1.1. First-line pharmacotherapy for smoking cessation.22
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c. Smoking during pregnancy
It is well demonstrated that smoking during pregnancy is associated with
negative perinatal consequences, including miscarriage, prematurity, low birth weight,
increased fetal respiratory symptoms, and sudden infant death syndrome (SIDS) (3436). Although smoking is the leading preventable cause of perinatal morbidity and
mortality, the National Vital Statistics Reports found that greater than 10% of U.S.
pregnant women smoke during pregnancy (7). This percentage is likely to be
underestimated by approximately 25% due to biases in self-reporting (37). Kentucky has
more than double the national rate of pregnant women who smoke (Figure 1.2), with
some regions reporting rates approaching 50%. Clearly, this is a significant public health
concern that particularly affects women and neonates in Kentucky.

Figure 1.2. Prevalence of maternal smoking at any time during pregnancy: 46 states
and District of Columbia, 2014.7 Used with permission.

7

Multiple studies suggest that 20-30% of female smokers attempt to quit while
pregnant, but success is often temporary. A large clinical study evaluating the efficacy
and safety of NRT in pregnant smokers identified that the smoking rate declined from
21.3% to 9.4% at the time of delivery in the NRT group compared to a decline from
11.7% to 7.6% in the placebo group (38). In a small self-report study of 134 women,
25% of participants reported a relapse by 1 month postpartum, while another large study
with 1550 women surveyed via telephone interview reported that the majority of
participants relapsed by one year postpartum (39, 40). Factors affecting smoking relapse
are similar to those that cause active smoking during pregnancy, with a stronger
association with lack of motivation and exposure to cigarette smoke (41). This signifies
the importance of support from family members and the society in achieving a
successful smoking cessation. Pregnant women are likely to achieve short-term
abstinence if their primary concern is the health of the fetus while those who are
concerned about the health of both fetus and self are likely to achieve long-term
abstinence (41). Pregnant smokers should be educated that postpartum abstinence is
also important in protecting the mother and the newborn since nicotine accumulates in
breastmilk, which can continue to affect neonatal development (42).
The intrauterine condition is critical for the proper growth and development of
fetal organs, and the fetus is vulnerable to any subtle changes in this environment. In the
early 1990s, a series of epidemiological studies reviewing birth and death records
revealed the association between poor intrauterine nutrition and adult cardiac/metabolic
diseases, suggesting the impact of “fetal programming” on adult health outcomes. This
has become known as the Barker Hypothesis and has stimulated active research that
expands beyond nutritional status during gestation to include the link between various in
utero environmental exposures and negative health consequences, such as pregnancy
smoking and fetal health (43, 44). Many studies and meta-analyses report intrauterine
growth retardation in both genders, as measured by birth weights, compared to
newborns of non-smoking mothers, accounting for 20-30% of low birthweight cases, in
these infants. Other measures of growth retardation are suggested by data showing an
impact on birth length as well as head circumference (45, 46). Dose-response
relationships between maternal smoking and the risk of stillbirth, neonatal death, and
perinatal death are also observed (47, 48). Other serious adverse outcomes include
sudden infant death syndrome (SIDS), fetal congenital heart defects, decreased
pulmonary function, obesity, neurobehavioral alterations such as decreased cognitive
8

function and attention deficit hyperactivity disorder (ADHD), and many more. These
characteristics can be presented during neonatal/infant periods as well as during
childhood (45, 49).
Consequences of developmental cigarette smoke exposure appear to be the
greatest during the third trimester, and the rate of health complications in infants born to
mothers who smoked only late in pregnancy is comparable to newborns whose mothers
smoked throughout pregnancy (50, 51). For example, a study evaluating benefit of
reducing the number of cigarettes smoked as opposed to a complete abstinence found
that the association between the level of cigarette smoke exposure and birthweight was
strongest during the third trimester. Interestingly, the association was only true when the
number of cigarettes used daily was less than eight cigarettes (52). Additionally, early
smoking cessation was associated with preterm birth rates comparable to nonsmokers
(28.9% vs. 29.3%), while smoking during the third trimester or throughout pregnancy
resulted in a significantly increased rate of preterm birth (43.9%) (53). This demonstrates
that smoking cessation should be encouraged as soon as possible, prior to reaching the
third trimester, and the use of less than eight cigarettes per day, and not any arbitrary
reduction in cigarette use, may result in observable changes in the birth outcome.
Although results vary based on an individual’s tobacco dependence and lifestyle,
interventions to support continued abstinence throughout pregnancy will certainly reduce
perinatal morbidity and mortality.
Gene expression and cellular changes induced by developmental cigarette
smoke exposure can cause damage that is amplified after birth. For example, a study of
2295 non-smoking patients who were exposed to parental cigarette smoke
developmentally showed a decline in pulmonary function test in adulthood, measured by
forced expiratory volume in 1 second (FEV1). This decline was associated with maternal
smoking, but not paternal smoking, and there was 3 to 5 years’ loss of function if
mothers smoked more than 25 cigarettes per day. This suggests that damage induced
prenatally can become permanent (54). In a study that investigated the association
between epigenetic modifications and in utero smoking exposure in cord blood of 1062
newborns identified differential DNA methylation patterns in several genes. These genes
include CYP1A1, AHRR, and GF11, which are known to participate in detoxification and
clearance of toxic tobacco components (55). Influence of maternal cigarette smoking on
epigenetic changes of newborns is a growing area of study, and although limited in
number, studies are starting to identify associations between altered gene methylation
9

from placenta, umbilical cord blood, and maternal blood with later offspring health
outcomes or predispositions for adult health risks, such as mental and behavioral
disorders (43, 45, 49).
The U.S. Preventive Services Task Force published clinical guideline for
behavioral and pharmacotherapy interventions for smoking cessation in adults in 2015
and recommends all currently marketed pharmacotherapeutic agents to pregnant
women for smoking cessation. However, the guideline states that there is limited
evidence for a clear benefit of all NRTs as well as bupropion SR and varenicline (56).
The FDA has assigned nicotine and nicotine containing products to Pregnancy Category
D, which describes that the potential benefits may warrant product use despite potential
risks found from investigational or marketing studies in humans (57). There are
thousands of active compounds known to be fetal toxins in cigarette smoke, such as
carbon monoxide, hydrogen cyanide, and nicotine. It is difficult to identify a causative
agent responsible for the adverse effects of maternal smoking on fetal health (15).
However, the main component of cigarette smoke, nicotine, easily crosses the placental
barrier and can be detected in the fetal circulation at levels exceeding maternal
concentrations by 15%, while amniotic fluid concentrations of nicotine are 88% higher
than maternal plasma (58). Nicotine also accumulates in breast milk, which can be
problematic due to subsequent ingestion by the infant (58). Therefore it is important to
consider the potential effects of nicotine itself upon the development of those exposed
prior to birth.
Teratogenic effects of nicotine on cognitive and neurobehavioral functions of
newborns are very well studied in animal models at various doses, and alterations in
motor, sensory, and cognitive functions are suggested to continue into childhood in
humans (Reviewed in 59). In one study, rats exposed to nicotine prenatally displayed a
significant delay in reflex to orientation and gravity, as measured by righting reflex and
geotaxis tasks, and a decreased exploratory activity compared to saline exposed rats.
Cognitive learning and memory functions were assessed by avoidance of stimulus, and
it was observed that a greater percentage of rats exposed to nicotine in utero were poor
learners. This was observed in rats both at 60 days and 6 months after birth, suggesting
chronic adverse effects of gestational nicotine exposure (59).
Studies have not definitively stated whether NRT use achieves successful
abstinence rates and is without adverse effects to mothers or newborns. For example,
one clinical study comparing the efficacy and safety of NRT patches (15mg per 16
10

hours) to placebo during pregnancy concluded no significant benefit in increasing the
rate of abstinence until delivery (38). While this study did not find differences in the rate
of adverse pregnancy or birth outcomes, interpretation of findings are limited by a low
adherence rate (7.2%), which is consistent with findings from other trial (60). One
plausible explanation for ineffectiveness is the enhanced clearance of nicotine and its
metabolite cotinine during pregnancy (60% and 140%, respectively) as well as a shorter
half-life of cotinine (8.8 vs. 16.6 h) (61). However, dose adjustment of NRT patches to
saliva cotinine levels still resulted in a comparable rate of relapse to placebo (62).
Despite several concerns and uncertainty regarding efficacy and safety of NRT,
many international guidelines generally advocate its use during pregnancy for those who
may benefit from therapy, such as individuals who failed to achieve successful cessation
with behavioral therapy alone. The US Public Health Service Clinical Practice Guideline,
the Society of Obstetricians and Gynecologists of Canada, and the US Preventive
Services Task Force together address this topic and make a statement that while NRT
reduces the number of cigarettes smoked in general population, studies have not
demonstrated the same results during pregnancy (3, 56, 63). In this regard, it is
suggested that physicians clearly communicate pros and cons of NRT use to their
patients and make clinical judgement when recommending such therapy.
Increased risk of respiratory anomalies has been suggested from a large study
investigating the association between pregnancy NRT use with major congenital
anomalies (MCA) in offspring (35). This study included nearly 200,000 children born in
the UK over a 10 year period based on the availability of mother-child primary care
records for diagnoses of MCA and for the prescription of NRT. By designating the NRT
group as those who had a prescription during the first trimester or 1 month prior to
conception, the study investigated the effects of in utero nicotine exposure during the
early stages of fetal development. The absolute risk of MCAs was comparable between
the NRT group and the smoking group, both of which were higher than the control group.
No statistically significant changes were observed in the risk of all MCA combined in the
NRT group compared to the smokers or the control group, but the risk of respiratory
anomalies was significantly higher than the control group as well as the smoking group
(OR: 4.65, 99% CI 1.76-12.25; p<0.001 and OR: 3.49, 99% CI 1.05-11.62; p<0.007,
respectively). This study highlights that the use of NRT in pregnancy is not without
serious health consequences, some of which may be comparable to the effects caused
by smoking (35).
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Moreover, studies assessing maternal smokeless tobacco use demonstrate a
negative association with perinatal outcomes, including preterm birth, stillbirth, and
neonatal apnea, that are comparable to those observed with cigarette smoking (64-66).
These studies were conducted using birth records of approximately 600,000 Swedish
citizens, and the pregnant women were divided into smokeless tobacco users, light
smokers (1-9 cigarettes/day), heavy smokers (≥ 10 cigarettes/day), and non-smokers
based on the information collected before the 15th week of gestation. Compared to nonsmokers, risk of preterm birth and stillbirth was increased in both smokeless tobacco
users and smokers, although heavy smokers were associated with a greater increase
than smokeless tobacco users or light smokers (64, 65). Results of neonatal apnea
demonstrated approximately a twofold increase in the smokeless tobacco users that
remained unchanged when adjusted for gestational age, fetal growth, and gender, while
cigarette smokers were associated with a 50% increase only before the adjustment but
not after (66). This is surprising as this data suggests that smokeless tobacco has a
greater negative impact on neonatal apnea. The authors proposed differences in PK
parameters of nicotine from smokeless tobacco, which is similar to those of NRT but not
cigarette smoking, as a possible explanation.
It is impossible to identify a single agent responsible for the negative perinatal
outcomes as various factors, including the timing and the level of tobacco exposure,
influence the outcomes collectively. Furthermore, physiological effects mediated by
smoking may differ from one organ system to another. Nonetheless, these studies
strongly suggest that nicotine is a critical toxin in cigarette smoke whose effects should
not be underestimated nor be considered a safer alternative to smoking during
pregnancy.
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B. Smoking/nicotine and Immunity
a. Overview
Cigarette smoke contains thousands of compounds with immunotoxic properties,
including nicotine and polycyclic aromatic hydrocarbons (15). In addition to commonly
known perinatal adverse health effects, cigarette smoke affects both the innate and
adaptive immune responses in a number of ways, including an impact on macrophage
function. Decreased levels of pro-inflammatory cytokines and impaired bactericidal
properties have been observed in pulmonary macrophages exposed to cigarette smoke
(67). Maternal smoking both before and after birth is a major threat to respiratory health
of newborns, and the timing and the level of exposure appear to have a significant
impact on the proper development of immune function and its capacity, as the
development of the immune system continues after birth (68).
Despite advances in the development of anti-infectives and other public health
measures, infectious diseases remain a major contributor of widespread morbidity and
mortality in the United States as well as worldwide. Rates of hospitalization from
infectious diseases fluctuate due to outbreaks of antibiotic-resistant organisms (69). In a
2009 report, the leading cause of infectious disease hospitalization was attributed to
respiratory tract infection, and the burden was highest among young children (aged < 5
years) (69). Similar observations were reported from retrospective case-control analyses
evaluating infectious diseases hospitalization and mortality outcomes in infants
developmentally exposed to maternal cigarette smoke (70). There was a dosedependent association between maternal smoking and morbidity outcome due to
infectious disease, and infection was a significant contributor of infant mortality,
particularly within the first two days of hospitalization (32.4%). Among several types of
infections, respiratory infection had the strongest association with infant hospitalization.
Additionally, this observation was independent of birthweight and gestational-age,
suggesting other potential mechanisms that adversely affect immune function in infants
exposed to cigarette smoke in utero (70).
Cigarette smoke is reported to have both pro-inflammatory and anti-inflammatory
effects that are mediated by different toxic components. The overall impact of cigarette
smoke on the function of immune cells and health of an individual depends on the
chronicity of the tobacco use as well as the sum of the effects caused by the toxins, and
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the extrapolation of this data should be cautiously considered when used in making
therapeutic recommendations, especially to a pregnant smoker (71).
In this section, the effects of cigarette smoke, and those specifically attributed to
nicotine, on the respiratory immune cell properties and functions, particularly the alveolar
macrophages, will be reviewed. Additionally, data describing the impact of cigarette
smoke on immunity will be compared to what is known of the impact of nicotine alone,
because the distinction between the two is important when considering the degree to
which NRT should be recommended during pregnancy. Finally, the impact of
developmental nicotine exposure on fetal immunity will be discussed, as this will set the
groundwork for establishing safety of NRT during pregnancy and highlight whether NRT
can be considered less harmful than smoking in pregnancy.

b. Respiratory Immune Defense
The risk of respiratory infection is greatly increased with both active and passive
cigarette smoke exposure and alterations of host defense are responsible for increased
susceptibility to infections in smokers. Normal flora of the respiratory tract are disrupted,
allowing colonization of pathogenic bacteria, such as H. influenza, S. pneumoniae, and
M. catarrhalis (72). Pseudomonas aeruginosa, which is an opportunistic gram-negative
nosocomial pathogen, rarely causes lung infection in healthy population, but the risk is
increased in patients with underlying medical conditions, such as chronic obstructive
pulmonary disease (COPD) and malignancy (73, 74). Two possible mechanisms
describe how cigarette smoke contributes to the altered respiratory immune defense and
therefore increased risk of infection by pathogenic or opportunistic bacteria: 1)
physiological and structural changes in the host and 2) disruption of normal immune
function. These changes occur simultaneously and all modulations mediated by cigarette
smoke collectively alter the overall balance of the immune system (72).
Lungs physiologically can be divided into two compartments: the conducting
airways, comprised of airway epithelial cells and secretory cells that act as the first line
of defense, and the lung parenchyma comprised of alveoli where gas exchange occurs
(75). The respiratory tract is constantly exposed to the external environment and
homeostasis is maintained by distinct groups of immune cells that mediate inflammatory
and anti-inflammatory responses to antigens in a coordinated manner (Figure 2.1). In the
conducting airways, the epithelial cells form physical barriers to exclude incoming
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antigens and particles that have gained access. These particles are removed from the
lungs by the ciliated pseudostratified columnar epithelial cells. Additionally, a highly
developed network of immune cells, including dendritic cells and macrophages, populate
the airways and the alveolar spaces to properly respond to a wide range of pathogens
and to initiate inflammation (76). The lung parenchyma is populated mainly by the
alveolar macrophages (AM) that make up 90% of the total immune cells, with the
remainder composed of dendritic cells, T cells, and B cells. Upon exposure to
pathogenic environmental antigens, airway epithelial cells detect conserved structural
motifs of microorganisms and allergens via surface receptors, such as toll-like receptors
(TLR), to signal both the innate and adaptive immune responses. They also secrete a
large array of antimicrobial substances and effector molecules to kill infectious agents,
recruit other immune cells, and support their function and survival during infection. For
example, nitric oxide (NO) released from epithelial cells is a free radical with potent
antimicrobial effects and tissue damaging effects, augmenting the inflammatory
response at the site of infection. Chemokines and cytokines, such as neutrophil
attractant IL-8 and granulocyte/macrophage colony-stimulating factors (GM-CSF) aid the
survival and recruitment of inflammatory cells (75, 77).
Dendritic cells (DCs) are known as professional antigen presenting cells that
develop from bone marrow-derived precursor cells and migrate to various tissues,
including the airways. They have the ability to recognize a variety of stimuli through the
expression of pathogen-associated molecular pattern (PAMP) receptors (78). During
active infection, DCs take up antigens and migrate to the draining lymph nodes, where
they interact with naïve T lymphocytes that recognize these molecules and undergo
proliferation and differentiation into subtypes of T cells, including helper, cytotoxic, and
regulatory T cells. Subsequently, T cells migrate back to the inflamed tissue via the
lymphatics and circulation and remove specific pathogens (78). Similarly, antibody
producing B lymphocytes are activated by antigens presented by DCs, which cause B
cells to migrate to the T lymphocyte zone in the lymph nodes, allowing for T and B
lymphocyte interactions required for optimal response (79).
Macrophage interaction with DCs is also important in maintaining homeostasis at
steady-state and inducing robust inflammatory responses during active infection.
Macrophages initially limit antigen acquisition by DCs by phagocytosing various antigens
inhaled from the air. This mechanism prevents unnecessary stimulation of the immune
response and lung damage from inflammation. However, macrophages become
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saturated with actively replicating microbial antigens upon infection, which causes
spillover of antigens into DCs and induces a robust immune response (80). Smoking,
and specifically nicotine, exposure alters the ability of macrophages to perform these
functions.

Figure 2.1 Antigen acquisition and transport in the lungs.75 Used with permission.
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Smokers are known to have increased risk of respiratory infection and other
pulmonary diseases, in part due to epithelial cell modifications induced by toxic
substances in tobacco that alter the integrity of epithelial defense mechanisms.
Exposure of human bronchial epithelial cells to 2.5% and 5% cigarette smoke extract
(CSE) for 28 days was shown to significantly increase the number of secretory Clara
cells and goblet cells while the number of ciliated cells was significantly reduced (81).
Similarly, mice exposed to cigarette smoke inhalation exhibited hypertrophy of the Clara
cell as well as hyperplasia of the basal and squamous cells when exposed to the
combination of cigarette smoke and the carcinogen N-nitroso-N-methylurethane (NMUT)
via nebulization. These mice were kept in a chamber for 192 days (6 hours/day, 5
times/week), thus demonstrating chronic effects of cigarette smoke exposure (82).
Additionally, alterations in epithelial and alveolar permeability are also associated with
cigarette smoke exposure, and this was linked to the damage and reduction in the
number of gap junctions (83). In this study, human bronchial epithelial cells (16HBE14o-)
were exposed to 10% cigarette smoke extract (CSE) for 72 hours, and proteins
associated with tight junctions, such as occludin (OCLN) and Zonula occludens (ZO-1,
ZO-2, ZO-3), were visualized via immunofluorescence staining. Compared to untreated
cells, those exposed to 10% CSE demonstrated discontinuous, fragmented tight
junctions, suggesting the negative effects of CSE on cell integrity (83). While it is certain
that these toxic cellular effects influence infection directly, these changes in the airway
epithelium likely also impact the function of immune cells in the airways.
The ability of immune cells to respond to and clear bacteria are compromised
upon cigarette smoke exposure (84, 85). Cigarette smoke leads to an influx of innate
immune cells, including neutrophils, macrophages, and dendritic cells, but their ability to
phagocytose microbes, generate respiratory burst, and present antigens are impaired.
Downregulation of surface receptors involved in pathogen recognition has also been
reported, signifying a defect in the initial sensing of pathogens (86, 87). These aspects
will be discussed in Section d of this chapter. Dendritic cells, critical in bridging the
innate and adaptive immune responses, have reduced expression of the co-stimulatory
molecules CD80 and CD86 as well as antigen presenting MHC Class II molecules.
Additionally T-cell activation, proliferation, and production of cytokines are suppressed
by cigarette smoke exposure (72, 86). While multiple cell types are impacted, this thesis
will focus mainly on macrophage function and characteristics in response to nicotine
exposure, which will be discussed in the next section.
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c. Macrophages

Macrophages are a subset of innate immune cells derived from circulating
peripheral blood mononuclear cells (PBMC) that differentiate into tissue-resident cell
phenotypes, such as microglia in the brain, Langerhans cells in the skin, Kupffer cells in
the liver, and alveolar macrophages in the lungs. Alveolar macrophages reside at the
interphase between the external environment and lung tissue and function in part to
remove innocuous substances as well as cell debris generated during normal cellular
processes in a healthy host. All macrophages have similar function as the primary
phagocytes of the innate immune system. Upon contact with a pathogen, alveolar
macrophages secrete various pro-inflammatory mediators, such as IL-1, IL-8, and TNFα,
to recruit neutrophils to the site of infection and generate subsequent inflammatory
responses for rapid clearance of the bacteria. After the initial surge of inflammatory
response and resolution of infectious challenge, macrophages remove apoptotic
neutrophils and other debris and secrete anti-inflammatory cytokines, such as TGFβ and
IL-10, to prevent lung injury from prolonged inflammation and to maintain tissue
homeostasis (88).
In order to function accordingly to a dynamically changing microenvironment,
macrophages take on different phenotypes defined by gene expression patterns that
induce various functions. Two such subsets are classically activated macrophages (M1)
and alternatively activated macrophages (M2). This classification is derived from the
Th1/Th2 paradigm of the CD4+ T helper cells, which also take on two different
phenotypes. Differentiation into Th1 and Th2 cells depend on the cytokine milieu of the
environment, with IL-12 and IL-4 inducing Th1 and Th2 responses, respectively.
Subsequently, Th1 cells produce its signature cytokine IFNγ that mediates a strong proinflammatory response. IFNγ generates antimicrobial effector molecules, such as NO,
and pro-inflammatory cytokines and induces M1 macrophage polarization. M1
macrophages also produce IL-12, which further promotes Th1 polarization, thus
perpetuating the pro-inflammatory cycle. Conversely, Th2 polarized cells produce IL-4,
IL-5, and IL-13 that induce M2 polarization and also amplify proliferation and
differentiation. Late in response to bacterial pathogens, M2 macrophages mediate antiinflammatory response by producing low levels of IL-12, shifting the balance away from
Th1 cells, and generating mediators involved in tissue remodeling, such as TGFβ1 (89,
90).
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One main distinction between M1 and M2 macrophages is highlighted by a shift
of L-arginine metabolism into urea and ornithine by upregulating arginase expression in
M2 macrophages, which results in cell repair through enhanced collagen synthesis and
cell growth. M1 macrophages, on the other hand, produce inducible nitric oxide synthase
(iNOS) that competes with arginase for the same substrate, L-arginine, but produces
citrulline and NO, which have potent antimicrobial activities (Figure 2.2) (90, 91). M1
macrophages also secrete high levels of the pro-inflammatory cytokines IL-6 and TNFα
as well as reactive oxygen species (ROS). In addition to arginase production, M2
macrophages are characterized by the expression of surface molecules Ym1, Fizz1,
CD36, and CD206 and by production of high levels of IL-10 and low levels of IL-12 (90).
In the absence of iNOS, M2 macrophages display more effective phagocytic activity than
bactericidal activity. These two opposing functions of M1 and M2 macrophages maintain
balance between homeostasis and inflammation, and dysregulation of this balance may
explain why certain populations, such as smokers, are more prone to immunologic
diseases.

Figure 2.2 Catabolism of L-arginine in M1 and M2 macrophages.90 Reprinted with
permission.
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d. Effects of cigarette smoke and nicotine exposure on macrophage
functional characteristics
Effects of cigarette smoke
Numerous in vitro and in vivo studies suggest functional and phenotypic
alterations of macrophages upon exposure to cigarette smoke. Mice exposed to
cigarette smoke (CS) for 6-8 weeks showed a worsened clinical status after P.
aeruginosa infection as measured by weight loss (74). Several observations from the
mice in this study provide possible explanations for the effects of CS on outcomes. First,
CS-exposed mice were associated with increased bacterial burden in the lungs and an
increased inflammatory response, suggested by higher numbers of neutrophils and
mononuclear cells in the lungs. These mice also had increased levels of proinflammatory cytokines, including TNFα, IL-1β and IL-6, and monocyte chemo-attractant
protein-1 (MCP-1) and macrophage inflammatory protein-2 (MIP-2) chemokines in the
lungs post-infection. Investigators then studied the impact of CS exposure on alveolar
macrophage responsiveness to an infection as a possible explanation for these
observations. Interestingly, alveolar macrophages isolated from CS-exposed mice
produced significantly lower levels of TNFα and IL-6 than sham-exposed mice, as
opposed to the observed increase of these cytokines in the lungs. This may be a result
of a feedback response to a dampened production of inflammatory mediators by alveolar
macrophages (74). Similarly, intratracheal lung infection with Streptococcus pneumoniae
in mice exposed to CS for 5 weeks resulted in a worsened clinical outcome, measured
by clinical appearance score and core body temperature. Post-infection bacterial burden
was significantly higher in the lungs of mice exposed to CS, and this group was
associated with higher levels of IL-1β, IL-6, IL-10, MIP-2, and TNFα in their lungs 48 h
post-infection. Furthermore, phagocytic capacity of macrophages isolated from CSexposed mice was decreased by 40%, suggesting reduced bacterial clearance and
prolonged infection that led to increased inflammatory cytokine production (92).
The impacts of CS on human alveolar macrophages appear to parallel those
observed in animal studies. Alveolar macrophages isolated from lung lavage fluids of
smokers and non-smokers exhibited a similar phagocytic ability against Listeria
monocytogenes infection but the mean phagocytic index was decreased in smokers.
Moreover, they were inefficient at killing ingested bacteria compared to those of nonsmokers, as measured by bactericidal activity (93).
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Other important aspects of macrophage function involve recognition of and
interaction with pathogenic molecules through surface receptors. CD14 and TLR4 are
macrophage surface receptors that recognize and bind to bacterial endotoxin (LPS).
Activation of these receptors induces downstream signaling pathways that initiate the
production of pro-inflammatory cytokines, such as TNFα, IL-1β, IL-6, and IL-8 (94). Pretreatment of alveolar macrophages isolated from murine lung lavage fluids with CS
resulted in a significant reduction of receptors expressed compared to non-CS treated
macrophages (95). This observation may explain the decreased production of proinflammatory cytokines, as a result of reduced recognition, by CS-exposed
macrophages, as discussed earlier. Another important surface receptor, CD11b, is
highly expressed by monocytes/macrophages and has an important role in phagocytosis
of apoptotic cell debris. The percentage of macrophages expressing CD11b was
reduced when mice were exposed to CS for 10 days (95). This can lead to a critical
functional deficit in regulation and resolution of inflammation. In fact, alveolar
macrophages isolated from smokers displayed insufficient phagocytosis of apoptotic
cells when compared to those of non-smokers (87). In this study, alveolar macrophages
were purified from the lung lavage fluid of patients with COPD who were smokers or exsmokers, healthy smokers without COPD, and non-smokers. Compared to non-smokers,
healthy smokers and both COPD groups were associated with macrophages that had
decreased ability to phagocytose apoptotic epithelial cells (87). Similarly, phagocytosis
of apoptotic neutrophils was depressed when murine alveolar macrophages were pretreated with CS (96). Apoptosis is programmed cell death that is tightly regulated to
maintain an intact cell membrane during the process and to prevent release of toxic
substances to neighboring cells. Inefficient ability to phagocytose apoptotic cell debris by
macrophages upon CS exposure is concerning, as this can lead to tissue damage by
inappropriately releasing noxious cytoplasmic contents into the environment (86, 88).
Macrophage phenotypic changes triggered by cigarette smoke are also
noteworthy as this leads to restricted functional capacity during a host’s response to
infection. Alveolar macrophages recovered from bronchoalveolar lavage (BAL) of
healthy smokers revealed gene profiles and protein production characteristics that were
associated with a macrophage shift toward an M2 phenotype, both at steady-state and
after LPS stimulation, when compared to that of healthy non-smokers. This was
characterized by decreased expression and secretion of TNFα, IL-1β, IL-6, and IL-8 and

21

elevated expression of genes related to IL-4 and a minimal to modest elevation of IL-10
expression and secretion (97, 98).
In summary, findings from animal and human studies suggest that smoke
exposure causes a defect in alveolar macrophages to recognize and respond to
pathogens, which result in exaggerated and prolonged inflammation as well as worse
clinical outcomes. Macrophages display distinct features upon exposure to CS that are
different from those not exposed to CS.
Effects of nicotine
There are thousands of chemical compounds in cigarette smoke capable of
mediating various biochemical effects in exposed tissues. It is difficult to isolate a single
agent responsible for the observed immunosuppressive effects on macrophages, and
little is known about the effects of cigarette components separately. However, many
studies suggest that nicotine may be driving the biochemical changes. Furthermore,
because smoking cessation products contain nicotine as the main component to help
with withdrawal symptoms and craving, its impact on immune function should be closely
evaluated, as recommendation of such product use during pregnancy introduces two
major issues: 1) effects of nicotine directly on immune cells and 2) effects of in utero
nicotine exposure on development of the immune network and response.
Several studies report nicotine-induced changes in macrophage characteristics
both at steady state and after stimulation that display a decrease in pro-inflammatory
protein production. In one study, murine alveolar macrophage cell lines were infected
with Legionella pneumophila and treated with various concentrations of nicotine to
determine its immunosuppressive properties as well as the mechanism. Results were
similar to the changes observed after the exposure to cigarette smoke, highlighted by
enhanced bacterial growth, downregulated secretion of IL-6, IL-12, and TNFα and
minimal effect on IL-10 concentrations. Additionally, the same modulations were
observed when dimethylphenylpiperazinium (DMPP), a nonselective nicotinic receptor
agonist, was administered (99), suggesting that different types of nAChR may be
involved in mediating these changes. Another study observed a nicotine-induced shift
from M1 to M2 phenotypes, characterized by expression of surface markers, cytokine
profile upon LPS stimulation, and T cell proliferation (100). In this study, human
peripheral blood monocytes (PBMCs) were differentiated into M1 or M2 macrophages
with granulocyte-macrophage colony-stimulating factor (GM-CSF) or macrophage
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colony-stimulating factor (M-CSF), respectively, and also in the presence of nicotine to
generate nicotine-exposed M1 (Ni-M1) and nicotine-exposed M2 (Ni-M2) cells. Although
Ni-M1 retained M1 characteristics, increased expression of CD14 and CD163 and
decreased expression of CD206 and CD11b suggest possible skewing of Ni-M1 into an
M2-like phenotype. Upon stimulation with LPS, cytokines produced by Ni-M1 were
different from M1 polarized macrophages, suggested by a significantly lower IL-12
production and high MCP-1 production. Macrophage/T-cell co-culture experiments
further suggested that Ni-M1 macrophages resemble M2 macrophages rather than M1
macrophages, as demonstrated by a reduced production of IFNγ and elevated IL-10
production (100).
Overall, data suggest strong similarities between the changes driven by cigarette
smoke and nicotine alone in various host defense mechanisms. This signifies that
harmful effects can be caused by nicotine administration. Nicotine replacement products
could modulate immune responses and increase the risk of infection, especially in
vulnerable populations, such as pregnant women and their developing fetuses and
newborns.

e. Impact of in utero nicotine exposure
NRT use during pregnancy should be cautiously recommended due to the ability
of nicotine to cross placental barrier easily, given its lipophilicity. Cigarette contains
immunomodulatory molecules and infants exposed in utero have a greater risk for
several developmental impairments, such as intrauterine growth retardation, premature
birth, compromised lung function, and altered immune defense. It is likely that these
impairments result from an accumulation of physiological changes mediated in utero (48,
101). However, little is known about the contribution of nicotine alone to observed
impairments and the extent of its contribution during development, thus raising the
question as to whether nicotine can be considered less threatening than smoking during
pregnancy.
Epidemiologic and animal data raise concern for the role of developmental
nicotine exposure in inducing changes that result in negative health outcomes.
Increased risk of childhood allergic airway disease, such as asthma, is one example that
has a strong association with exposure to cigarette smoke during fetal development
(102). Animal study data supplements the general notion that nicotine may be
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responsible for inducing parameters associated with increased risk of asthma (103).
When pups were exposed to nicotine during gestational periods, they had increased
total airway resistance, decreased total airway compliance, and increased tracheal
constriction after birth. In another study, baseline cytokine profiles of neonatal lung from
in utero nicotine exposed mice displayed increased IL-13 and decreased IL-1β mRNA
expression as well as increased TGFβ1 protein in the epithelial lining fluid at postnatal
day 7 (104). This demonstrates a shift towards an anti-inflammatory set point.
Furthermore, in utero nicotine exposure resulted in elevated mRNA expressions of M2
specific markers at baseline, including arginase-1, Ym-1, and fibronectin. A profound
reduction in phagocytic ability of neonatal alveolar macrophages was also observed after
in utero nicotine exposure (104). Importantly, most of the observations mirror the
changes demonstrated with post-natal nicotine exposure.
T lymphocytes have also been shown to be affected by developmental nicotine
exposure. Lymphoid cell precursors are generated in the bone marrow and migrate to
the thymus, where they undergo stages of positive and negative selections and
differentiate into subsets of T cells. Therefore, it is crucial that proper development of the
fetal thymus is maintained during the gestational period to establish fully functioning and
well-balanced T cell lineages. Th1 and Th2 cells, as discussed earlier, are two subsets
of Th cells whose balance is important in regulating the immune response and
maintaining homeostasis. However, daily injection of nicotine in pregnant mice
generated offspring with a shift towards a Th2 bias (105). In this study, immunoglobulin
(IgG2a and IgG1) levels were used as a marker of Th1 and Th2 responses, respectively.
Upon immunization with an antigen, serum IgG2a levels were reduced while IgG1 levels
were increased significantly in the pups. Additionally, IL-4 concentrations were higher in
the serum of pups developmentally exposed to nicotine. Abnormal development of
thymus tissue through exposure to nicotine was suggested by increased apoptosis of T
cells and lower thymus weights in fetal thymus harvested at gestational day 18.
Moreover, changes in T cell phenotypes, including cells that were double negative for
CD4 and CD8 expression and single positive CD4 or CD8 expression, were observed in
this group. Improper generation of T cell subsets as well as reduced output of T cells as
a result of increased apoptosis can lead to dysfunctional effector T cells in the periphery
(105).
Prenatal nicotine also affects lung development and function postnatally. Animal
studies demonstrated a reduction in pulmonary function parameters due to altered
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airway structure as well as alveolarization of the lungs induced by prenatal nicotine
exposure (106). This provides a possible explanation for the increased susceptibility to
respiratory infections in neonates and children exposed to nicotine developmentally.
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C. Non-neuronal cholinergic system and immunity
a. Overview
Acetylcholine (ACh) is a molecule known to scientists for more than 150 years. It
has been extensively studied and understood for its function as a neurotransmitter. Both
unicellular and multicellular organisms appear to have the capability to synthesize ACh
and possess components of the cholinergic system to various extents. This
demonstrates that ACh is a phylogenetically ancient molecule whose function in nonneuronal cells precedes that in neuronal cells (107). Recent interest in the role of ACh
apart from the nervous system has led to a better understanding of the wide distribution
of its synthesis and expression of its receptors in non-neuronal cells as well as its critical
function in human health and disease beyond the brain.
There are two types of ACh receptors, nicotinic and muscarinic receptors, and
both types are expressed in non-neuronal cells (4). As the name implies, nicotinic ACh
receptors (nAChR) can be stimulated by endogenous ACh as well as exogenous
nicotine, whereas muscarinic ACh receptors (mAChR) are stimulated by endogenous
ACh as well as muscarine, a molecule derived from a poisonous mushroom. Although all
nAChRs share this feature, affinity and specificity of ligands to the receptor may vary
based on the composition of receptor subunits, which can ultimately lead to various
degrees of physiological effects (108). This is of particular interest and concern for
pregnant women and developing fetuses prone to direct and indirect exposure to
environmental toxins capable of stimulating nAChRs, such as nicotine. As mentioned
earlier, children born to smoking mothers are at a higher risk of respiratory infection, and
cigarette smoke and nicotine are known to have immunomodulatory effects. Prevalence
of ACh and its components in non-neuronal cells early in the embryonic stage suggests
a possible role in normal development of fetal lymphoid organs and establishing the
underlying immune tone (109). Hyperstimulation of nAChR through exposure to cigarette
smoke and nicotine-containing products can lead to undesirable cellular and organ
development set at birth (110).
In this section the non-neuronal cholinergic system will be discussed with regard
to its expression, function, and role in human health with particular emphasis on
macrophages and the potential developmental effects of in utero nicotine exposure.
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b. Non-neuronal cholinergic system and human diseases
The term “cholinergic system” refers to the neurotransmitter ACh and the
components of its synthesis, transport, receptor binding, and degradation. ACh was the
first neurotransmitter identified in the 1920s and since then, its role in the neurons of the
central and peripheral nervous systems has been extensively studied. Choline
acetyltransferase (ChAT) is an enzyme responsible for catalyzing ACh from coenzyme A
(CoA) and choline in the cytoplasm of cholinergic neurons. Once synthesized, ACh is
stored in the synaptic vesicle and released upon depolarization of the neuron into the
synapse by exocytosis. Ligand bound ACh receptors (AChR) cause changes in
intracellular calcium concentration via ion-gated channel opening or by regulating
downstream signaling effector molecules. Unbound ACh is quickly hydrolyzed by
acetylcholinesterases (AChE) and the degraded components are recycled (4). There are
two different classes of ACh receptors, ionotropic nicotinic and metabotropic muscarinic
receptors, as their stimulation is induced by nicotine and muscarine, respectively (111).
Both types can be activated by endogenous ACh, and they are widely distributed
through the neuronal and non-neuronal cells. nAChR will be the main focus and
therefore will be discussed more in depth.
The nAChR is a member of the ligand-gated ion channel receptor family that
produces structures from combinations of five polypeptide subunits forming a functional
core (other members include GABAA receptors, 5HT3 receptors, and glycine receptors)
(112). Types of nAChR subunits include muscle subunits (α1, β1 γ, δ, ε) and neuronal
subunits (α2-7, α9-10, and β2-4), which can be further classified into α-bungarotoxin
sensitive α7-9 homopentamers and α-bungarotoxin insensitive heteropentamers (113).
Once endogenous ACh or exogenous nicotine binds to a receptor, it is stabilized in the
open conformation and causes depolarization of the membrane via cation influx. Various
combinations of these subunits contribute to the diversity of nAChR properties and
functions that are tissue specific. For example, receptors that contain α4 and β2
subunits, which are mainly found in the brain, have the highest affinity for nicotine.
Depending on the stoichiometry of the subunits, receptors may be more or less sensitive
for upregulation when a ligand is bound (113, 114). α7 nAChRs have the highest
permeability to calcium, which can lead to calcium-dependent downstream signaling and
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result in physiological responses, such as proliferation, angiogenesis, and apoptosis
(115).
Despite the vast majority of study dedicated to understanding the neuronal
cholinergic system, the complex and intricate network connecting nAChR to cellular
functions beyond the nervous system have only recently garnished attention. ACh has
been found to play a role in various non-neuronal cells, including epithelial, endothelial,
mesothelial, and immune cells. (108). In fact, ACh is ubiquitously expressed in
prokaryotic and non-neuronal eukaryotic cells, such as protozoa, fungi, and plants, and
components of the cholinergic system are also detected in these cells, demonstrating
the role of cholinergic communication in non-neuronal systems (111). Evolutionarily, this
indicates that the non-neuronal cholinergic system existed before the neuronal
cholinergic system. Therefore, the term “non-neuronal cholinergic system” has been
introduced to distinguish the newly discovered role of ACh and its components acting as
a local signaling “cytotransmitter” molecule, whereas the conventional “neuronal
cholinergic system” describes the role of ACh as a neurotransmitter, mediating rapid
communication between neurons and effector cells (116). The importance of the nonneuronal cholinergic system in human health is highlighted in many studies and nAChRs
have become a potential target for pharmacotherapy in a variety of disease states.
The role of the non-neuronal cholinergic system in pathogenesis is supported by
in vivo and in vitro studies of cancer, immune-related diseases, respiratory diseases,
and many more. Patients suffering from cystic fibrosis (CF) and COPD have impaired
mucociliary clearance, mucus hyperviscosity, increased risk for lung infection and
pulmonary function decline. It was observed that nAChRs are expressed at the apical
membrane of the ciliated lung epithelium and its co-localization with the cystic fibrosis
conductance regulator (CFTR) may be responsible for its regulatory role in CFTR
function. Absence of α7 nAChR led to lower mucus transport as well as higher
electrolyte concentrations in the mucus, similar to what is observed in CF patients. As
mentioned earlier, α7 nAChR has the highest permeability to calcium, which is an
important mediator in activating signaling cascade that ultimately activates CFTRmediated ion transportation. Coupling of α7 nAChR and CFTR function was further
validated by α7 nAChR agonist-induced calcium influx and activation of effector
molecules involved in CFTR activation as well as delocalization of CFTR in α7 nAChRdeficient mice. (117). In a human breast cancer cell line, elevated α9 nAChR mRNA and
protein expression levels were observed after 6 h of nicotine treatment (118).
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Proliferative properties induced by nicotine treatment were also demonstrated in other
cancer cell lines, including those from the lung, pancreas, stomach, and colon, mediated
via other nAChR subunits. One important component of cancer cells is the ability to
migrate and metastasize to a new region. Chronic nicotine treatment to lung and breast
cancer cell lines resulted in an altered regulation of adhesion molecules, including Ecadherin and β-catenin, and mesenchymal proteins, including fibronectin and vimentin.
As a result, nicotine-exposed cells demonstrated the ability to undergo an epithelialmesenchymal transition and gain a migratory phenotype (119, 120).
In non-neuronal cells, ACh acts in both an autocrine and a paracrine manner. For
example, ACh secreted from airway epithelial cells targets neighboring epithelial cells,
monocytes and resident macrophages that express AChRs (Figure 2.3). Stimulation of
nAChR expressed on circulating monocytes or macrophages leads to inflammatory or
anti-inflammatory effects (121). Reciprocally, nAChR expression levels can be regulated
by effector molecules of the immune cells, demonstrated by upregulation of α4β2
nAChR levels by TNFα released from macrophages. ACh released from airway epithelial
cells regulates their ciliary activity and proliferation, and this is supported by the fact that
small cell lung cancer cell growth is promoted by ACh released as an autocrine growth
factor (121).

Figure 2.3 Auto/paracrine role of epithelial ACh.121 Used with permission.
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c. Non-neuronal cholinergic system in immune cells and nicotine
Although ACh was first reported in the 1930s to be present in mammalian blood,
it was not until the 1980s that a sensitive and specific radioimmunoassay (RIA) for
detecting ACh was available to confirm its presence in mammalian plasma. The origin of
ACh in the bloodstream was found to be immune cells, particularly mononuclear
leukocytes (MNL). Nicotine administration in rabbits led to an increase in plasma ACh
concentration with a reduction in blood ACh levels in the presence of an AChE inhibitor.
Further analysis of blood components detected ACh contained in the MNL fraction only
and not in polymorphonuclear leukocytes (PMN) or the red blood cells. Subsequently,
the expression of choline acetyltransferase (ChAT) mRNA from a human leukemic T cell
line and mammalian blood and the expression of both mAChR and nAChR on most
immune cells led to the conclusion that ACh is synthesized by the immune cells
independent of that released from neurons (Reviewed in 122, 123).
The presence of cholinergic components in immune cells suggests that ACh
must have a role in regulating the immune response. In fact, stimulation of mAChRs or
nAChRs results in downstream signaling process and cellular response, such as
differentiation of CD8+ T cells, changes in the pattern of cytokine release, and
proliferation (124-127). Depending on the levels of expression and types of mAChR
and/or nAChR present on individual cell types, the overall biological changes induced by
stimulation of these receptors may vary. For example, M1 mAChRs appear to participate
in the differentiation of CD8+ T cells into cytolytic T cells while deletion of M3 or M5 or
combination of M2 and M4 mAChRs has no effect (124). Also, M1/M5 mAChR-deficient
mice showed reduced level of the pro-inflammatory cytokines IL-6 and IFNγ, whereas α7
nAChR-deficient mice were associated with increased level of the pro-inflammatory
cytokine TNFα (125, 127).
Although details concerning each type of AChR and the composition of its
subunits and their expression on immune cells are still being actively investigated, the
role of the cholinergic system in immune related diseases is apparent and has been
demonstrated in several disease models, including sepsis, colitis, and arthritis (128).
Particular attention was given to the role of the anti-inflammatory effects of α7-nAChR
stimulation on macrophages as a part of the ‘cholinergic anti-inflammatory pathway.’
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ACh treated human macrophages that were exposed to LPS displayed inhibition of
TNFα release through a post-transcriptional mechanism (129). Comparable inhibition
was observed with nicotine administration. Using the α7 nAChR antagonist, αbungarotoxin, the study concluded that α-bungarotoxin-sensitive nAChRs are
responsible for mediating the observed effects (129). Additionally, release of other proinflammatory cytokines, including IL-1β, IL-6, and IL-18, were also inhibited by ACh
treatment while no changes were observed in anti-inflammatory cytokine IL-10 release.
Subsequent studies identified that the α7 subunit is necessary for cholinergic-induced
anti-inflammatory responses, and this was further validated in vivo using α7 subunitdeficient mice. This study showed that cells release significantly higher amount of TNFα
after administration of endotoxin compared to wild-type mice (127). Later, it was
identified that T cells are responsible for producing ACh and regulating macrophage
cytokine release patterns as well (130).
It was discussed earlier that cigarette smoke and nicotine can suppress
inflammatory response partially by shifting macrophages towards an M2 phenotype.
Different compositions of nAChR subunits are capable of mediating this change with the
most studies performed to investigate the α7 subunit. Nicotine-induced suppression of
pro-inflammatory cytokines as well as antimicrobial activities to Legionella pneumophila
were observed in alveolar macrophages that express only α4β2 nAChR subunits, and
these effects were reversed with d-tubocurarine, a non-selective nAChR antagonist (99).
In a sepsis-induced acute lung injury (ALI) model with Escherichia coli, reduction in MIP2 production in bronchoalveolar lavage fluid and neutrophil migration into the lungs were
observed upon administration of α7 nAChR agonists, including nicotine. Pre-treatment
with nicotine led to a reduction in LPS-induced MIP-2 and TNFα cytokine production by
alveolar macrophages, which was reversed with α7 nAChR specific antagonist
methyllycaconitine (MLA). Similar results were seen with wild-type neutrophils and α7
nAChR-deficient neutrophils treated with nicotine, suggesting the expression of α7
nAChR on neutrophils and the functional regulation by α7 nAChR. Overall outcomes in
mice indicate that nicotine treatment aids in survival after intratracheal E. coli infection
and α7 nAChR plays an important role (131).
There is insufficient data regarding the role of non-neuronal cholinergic system in
immune cell development. However, it was observed that the non-neuronal cholinergic
system is developed and expressed early in life, during fetal hematopoiesis. This is
particularly important because, unlike in adults, hematopoietic stem cells (HSC) are
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generated initially in the yolk sac and then migrate to the fetal liver. Homing of HSC from
fetal liver to the bone marrow occurs towards the end of the gestational period. The
intrauterine developmental period is, therefore, crucial in the process of lymphopoiesis
and any disturbance in this process can lead to imbalanced immune cell populations that
can be amplified as a defect in the overall regulation of the immune system (132).
In fact, nicotine treatment was shown to change environments regulating
hematopoietic stem cells in the fetal bone marrow. The presence of ChAT, AChE, and
nAChRs was confirmed by gene expression profiling from embryonic stem cells, and
nicotine treatment led to impaired colonization of hematopoietic stem cells in the fetal
bone marrow. Furthermore, the cytokine production profile from bone marrow cells was
changed upon nicotine treatment such that hematopoiesis-supportive cytokines, such as
G-CSF and GM-CSF, were suppressed and Th2 T lymphocyte produced cytokine IL-4
was upregulated (109). Another study demonstrated that alveolar macrophages isolated
from mice exposed to nicotine developmentally had suppressed inflammatory response
mediated by α7 nAChR (104). Expression of α7 nAChR was increased in mice exposed
to nicotine in utero and its role in regulating macrophage function was demonstrated.
One such example is the increased expression of TGFβ1 by alveolar macrophages
harvested from the pups on post-natal day 7. However, this increase was attenuated in
α7 nAChR knock-out mice that were exposed to nicotine developmentally, suggesting
that α7 nAChR and other nAChR may be involved in mediating these changes.
Additionally, cells expressing markers of alternative activation, including arginase-1,
Ym1, and fibronectin, were increased in pups exposed to nicotine prenatally. This
observation was reversed in α7 nAChR knock-out mice. Reduction in phagocytic activity
against Staphylococcus aureus was displayed only in the macrophages expressing α7
nAChR, which is another noteworthy impact of in utero nicotine exposure and the role of
non-neuronal cholinergic system in mediating these effects. These findings raise
concern regarding the effects of in utero nicotine exposure on programming of
macrophage function and its tone set at birth, which can predispose neonates to various
immune-related diseases (104).
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D. Project Overview

The use of NRT during pregnancy is still without strong efficacy and safety evidence.
It should not be neglected or underestimated that nicotine itself poses harmful effects to
human health and potentially to proper development of fetal immunity. In order to state
that NRT is less harmful than smoking during pregnancy and recommend its use to
pregnant smokers, it is crucial to understand how in utero nicotine exposure affects
offspring and the extent of its effects. In this study, we administered nicotine to pregnant
mice via their drinking water to generate offspring that were exposed to nicotine in utero.
The immune response was then observed following P. aeruginosa lung infection.
Additionally, bone marrow cells were obtained from offspring mice and differentiated into
macrophages, which were then stimulated with LPS and various cytokines to observe
cellular responses ex vivo. Finally, a clinical study has been developed to examine the
impact of NRT on macrophage gene expression in neonates. Tracheal aspirate samples
from neonates will be collected and gene expression signatures will be compared to
correlate findings to different modes of in utero nicotine exposure. This step will aid in
identifying impacted genes and targeting future studies in this area. The central
hypothesis of this project is that in utero nicotine exposure will alter immune cell
disposition and function in response to P. aeruginosa lung infection. This will be
investigated through in vivo infection as well as ex vivo macrophage stimulation with
LPS.
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Chapter 2. Methods
A. Animal Work
a. Mice
C57BL/6 mice with a GFP tag on α4 nicotinic receptors were provided from the
Stitzel lab (University of Colorado at Boulder) and bred in-house for the experiments.
Mice were fed with either saccharin dissolved in water or nicotine dissolved in water (200
µg/L) ad libitum before and throughout pregnancy. This is a well-established model for
chronically administering nicotine to experimental animals and achieves plasma cotinine
levels within the range reported in human smokers (133). All animal studies and
procedures were approved by the University of Kentucky Institutional Animal Care and
Use Committee.

b. Intratracheal Infection
After weaning, 4-6 week old offspring were infected intratracheally with the
clinically derived mucoid strain P. aeruginosa M57-15. Bacteria were thawed from the
stock vial and grown in Trypticase soy broth (TSB) to late log phase at 37°C, which were
then incorporated into agarose beads by adjusting temperature of mineral oil and TSB
and swiftly mixing them. Once the beads had formed, they were washed multiple times
with phosphate buffered saline (PBS) to retrieve beads of various sizes ranging in 10100 µm. Visualization of beads was performed using an inverted microscope to confirm
the sizes and numbers of beads (134). The number of CFU was determined by
homogenizing the beads and growing the bacteria on Trypticase soy agar (TSA) plates
in multiple dilutions. The P. aeruginosa-laden agarose beads were diluted to the target
CFU for each infection. Beads were kept at 4°C and used within 1 week of preparation to
assure their quality and integrity. On the day of infection, mice were lightly anesthetized
with isoflurane aerosolized and 100uL of beads were instilled intratracheally using a
curved 24-gauage needle. The same volume was plated on Pseudomonas isolation agar
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(PSA) plates to ensure that mice were infected with desired inoculum. Daily weights
were recorded as a measure of morbidity.

c. Tissue Harvest
On post-infection day 5, mice were humanely euthanized by injecting 0.1mL of
SOMNASOL Euthanasia-III Solution (Henry Schein Animal Health, Dublin, OH)
intraperitoneally. Bronchoalveolar lavage fluid was collected by instilling 5 mL of buffered
solution containing 0.3 µM EDTA in 1 mL aliquots. This is representative of immune cells
located in the airway compartment and will be referred to as lung lavage (LL). The first 1
mL was collected and centrifuged to separate out cells and measure cytokine
concentration in the supernatant. Pelleted cells from this collection was combined with
the remainder 4 mL of lavage fluid samples. Lungs were then collected in RPMI medium
(Mediatech, Manassas, VA), minced with scissors, and incubated with 1mg/mL
collagenase A and 50 U/mL DNase for 1 h at 37°C. Digested lung tissue was then
pushed through a 70 µm mesh screen to create a single cell suspension and washed
with red blood cell lysis buffer (Quality Biological, Inc., Gaithersburg, MD) and PBS. This
is representative of immune cells located in the lung interstitium and will be addressed
as lung digest (LD). An aliquot of LD from each mouse sample was plated on PSA plates
in multiple dilutions to determine bacterial burden. Lastly, tracheobronchial lymph nodes
(LN) were collected and pushed through 70 µm mesh screens to create a single cell
suspension. Cells were then washed with red blood cell lysis buffer and PBS.

d. Flow Cytometry
Cells from LD, LL, and LN were incubated with panels of fluorescently labeled
antibodies (CD11b, CD11c, Ly6G, CD4, CD8, CD19, and CD44) to determine their
characteristics by surface marker expression. In excess of 50,000 events per sample
were acquired by the Attune Acoustic Focusing Cytometer (Life Technologies, Carlsbad,
CA), and data were analyzed by FlowJo software (Tree Star, Ashland, OR). Acquired
cells were gated for leukocytes and the percentage of each subset was multiplied by the
total number of cells.
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e. Cytometric Bead Array
Cytokine concentration from the first lung lavage wash as well as from the
supernatants collected from the human tracheal aspirate samples were measured using
cytometric bead array (BD Biosciences). The following cytokines were measured: IL-6,
IL-10, MCP-1, IFNᵧ, IL-12p70, and TNF-α. Briefly, detection beads are conjugated with
antibodies specific for each cytokine in the sample. Sample was mixed with the beads
and the mixture was added to phycoerythrin-conjugated detection antibody for 2 hours.
Fluorescence intensity for each analyte was then assessed via flow cytometry, with each
distinguished by gating on specific bead size, and compared to a standard curve of
known concentrations.

f.

Isolation and ex vivo stimulation of bone marrow-derived macrophages
(BMDM)

Primary macrophage cells derived from bone marrow were isolated and cultured
ex vivo to determine their responses upon stimulation and polarization. C57BL/6 mice
with GFP tag on nicotinic receptors described previously were used. Briefly, 4-6 week
old offspring from mice fed with either nicotine or saccharin dissolved in water during
gestation were humanely euthanized. Femurs and tibias from both legs were dislocated
by cutting off the patellar tendon and the foot, and the bones were isolated by removing
tissues and muscles. Bones were then flushed with 5 mL RPMI media by inserting 25gauge 5/8 inch needle into the bone cavity. This was repeated until all bone marrow cells
were removed and the bone appeared clear. Collected cells were centrifuged at 1200
rpm for 5 minutes and red blood cells were lysed using the lysis buffer. Bone marrow
cells were then washed and resuspended in complete RPMI (supplemented with 10%
fetal bovine serum, 2x10-5M 2-mercaptoethanol, 1% penicillin/streptomycin, 1%
glutamine) as well as L929 supernatant, which contains macrophage colony-stimulating
factors (M-CSF) to allow differentiation of hematopoietic bone marrow stem cells into
macrophages (135). Cells were initially cultured in petri dishes with media changed
every 2 days. On day 7, cells were replated in 24-well plates at 2x105 cells per well in
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complete RPMI media (without L929 supernatant) and treated with IFNγ (20 ng/mL),
IL4/13 (10 ng/mL), and LPS (50 ng/mL) for determination of arginase activity or cytokine
levels. Cells were incubated at 37°C and 5% CO2 for 24 hours.
g. Arginase Activity
Arginase activity was assessed by measuring urea concentration produced in the
arginase reaction. Arginase converts arginine into urea and ornithine, and the activity is
measured by the intensity of urea-chromogen complex, which produces a color change.
Prior to the assay, cell lysates were prepared using 0.4% Triton X-100 in 10 mM TrisHCl buffer with protease inhibitor cocktail (Pierce Biotechnology, Rockford, IL). Arginine
buffer was preheated to 37°C for 10 minutes and then combined with Mn solution to form
a substrate buffer. 10 µL of the substrate buffer was added to 40 µL of each sample on a
96 well plate and incubated at 37°C for 2 hours. The arginase reaction was terminated
by adding 200 µL of urea reagent and incubating the plate for 1 hour at room
temperature. Optical density (OD) of each sample was read using a 430 nm filter, and
the readings were normalized using OD of blank sample and water. One unit of arginase
is responsible for conversion of 1 µmole of L-arginine to ornithine and urea per minute,
and the values were additionally normalized to total protein concentration, using the
bicinchroninic acid protein assay (BCA) (Pierce Biotechnology, Rockford, IL).
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B. Human Study

a. Study Design
Pregnant women at the University of Kentucky Medical Center who gave birth to
pre-term (>24 weeks) and term infants were screened for inclusion. Initially, a
collaborating neonatologist identified potential participants based on general health of
the mothers and the newborns. After obtaining a consent from the mothers, a detailed
smoking history and medical history were obtained through a series of questionnaires
(Appendix I) and used to include or exclude patients from the study. Use of ≥ 5
cigarettes daily during pregnancy was required to be enrolled in the smoking group.
Women who used nicotine replacement products during pregnancy were stratified into
the replacement group. The control group was defined by no direct exposure to nicotine
during pregnancy. Informed consent and parental permission forms to include the
neonates in the study were provided at recruitment and signed informed consent was
required prior to participant enrollment (Appendix II). Patients were excluded if there
were known major fetal abnormalities, chemical/alcohol dependence, contraindication to
NRT, use of any forms of tobacco other than cigarettes or e-cigarettes, and any active
infection for either the mother or newborn at the time of delivery, before sample
collection. Premature infants requiring mechanical ventilation for reasons other than
assisting “physiologic normalcy” were excluded from the study. Chronic use of
medications known to pose immunomodulation, such as steroids, or have potential for
causing immunomodulation also met exclusion criteria.

b. Sample Collection and RNA isolation

Baseline data (date of birth, hospital number, ethnicity, medical history, daily
number of cigarettes smoked during pregnancy, time from last cigarette smoked/nicotine
replacement product use, partner’s smoking status, gestational age, signed consent
form, a list of acute/chronic medications, medications administered during current
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hospitalization, and indication of participant’s contact details) were collected through a
series of questionnaires as well as from the subject’s medical record (Appendix III).
Within the first week of birth, 0.5 to 1 mL of tracheal aspiration samples were
collected for a total of 2-3 samples per baby (up to 5 samples). Samples were
centrifuged at 4°C for 7 min at 300g to pellet the cells, and supernatants were saved and
frozen at -80°C for cytokine measurement. Cells were then washed 3 times with RPMI
and 1-2x106 cells were aliquoted and kept frozen in TRizol at -80°C for RNA isolation.
The remainder of cells were seeded at 2x105 cells per well in 24-well plates and
incubated at 37°C and 5% CO2 for 2 hr to isolate alveolar macrophages. After removing
non-adherent cells, macrophages were stimulated with 10 ng/mL of LPS from
Escherichia coli O55:B5 from EMD Millipore and 20 ng/mL of human interferon-γ
(eBioscience) (IFNγ) for 6 hours. Supernatants were saved for post-stimulation cytokine
measurement. Cells were placed in TRizol and frozen at -80°C for RNA isolation. RNA
isolation was performed using the Qiagen RNeasy Kit (Qiagen Sciences, Germantown,
MD) and quantified using a Nanodrop 2000 (Thermo Scientific, Wilmington, DE).
Once patients are recruited for the study, 3 groups (cigarette smoke vs. NRT vs.
no exposure) will be compared for 1) baseline RNA expression immediately upon
collection of the specimen and 2) after stimulation with LPS and IFNγ. Upon isolation of
RNA, microarray will be performed, using the TaqMan® Gene Expression Array Plates
(Applied Biosystems, Foster City, CA). TaqMan® arrays are flexible, affordable, and
convenient for gene expression analysis screening for specific biological pathways,
processes, diseases, or can be customized. These arrays each consist of 48 genes of
interest, such as TNFa, IL-1, IL-10, and CD86. A list of genes that will be assessed is
provided in Appendix I. RNA samples (0.1-10ug) will be converted into cDNA, and using
10-100 ng of cDNA per plate, Applied Biosystems real-time quantitative PCR instrument
will allow amplification of target genes. Gene expression can be measured by the
quantitation of cDNA relative to a calibrator sample, which serves as a physiological
reference. All quantitations will be also normalized to an endogenous control to account
for variability in the initial concentration and quality of the total RNA and in the
conversion efficiency of the reverse transcription reaction.

c. Statistics

39

Data are reported as mean ± SD and compared using GraphPad Prism
(GraphPad Software, La Jolla, CA, USA). Data were compared via two-way ANOVA,
followed by Bonferroni’s post-test individual comparisons, or t-test where appropriate.
Differences were deemed statistically significant at a p value < 0.05.
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Chapter 3. Results

In utero nicotine exposure negatively affects morbidity outcome
Mice exposed to either saccharin (Control) or nicotine in utero were infected with
P. aeruginosa to assess the impact of developmental exposure on complete immune
response. Daily weights were measured and mice that had weight reduction greater than
20% prior to the harvest were humanely killed. Pre-infection weights were comparable
between the two groups with the average weight of 21.37 g and 22.15 g for control and
nicotine group, respectively (Figure 3.1a). Infected mice lost weight initially but
recovered by the end of study period. While the pattern of weight loss was similar
between two groups, mice exposed to in utero nicotine displayed a greater weight
reduction, particularly on Days 2 and 3 (Figure 3.1b). This experiment was repeated
three times and, although no statistically significant differences were observed between
the groups in pooled data, similar weight loss pattern was observed with more
pronounced reduction in the nicotine group (Figure 3.1c).
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Figure 3.1 Baseline weight and post-infection weight reduction as a measure of morbidity. In
utero nicotine exposed mice were generated from pregnant mice fed with saccharin- or nicotinedissolved water throughout pregnancy. 4-6 weeks post-birth, mice were infected with agarose
beads containing bacteria. a) Baseline weight pre-infection. b) Post-infection weight changes from
a single experiment. c) Post-infection weight reduction from pooled data. Data represents the
mean ± SD of b) 7 or c) 16 mice per group. Significance is indicated for p values < 0.05 (*) and <
0.01 (**). Data was analyzed by two-way ANOVA.
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Pre- and post-infection cellular characteristics
A group of mice born to those fed with saccharin- or nicotine-dissolved water was
sacrificed without an infection to assess baseline characteristics (pre-infection, Day 0)
while another group underwent intratracheal infection with P. aeruginosa and were
sacrificed to compare cellular characteristics on Day 5 post-infection. Cells were
enumerated by Trypan blue staining using an automated cell counter and the
percentage of immune cell subsets in the lung digest, lung lavage, and lymph nodes
were determined by the surface receptor expression. The absolute number of each
subset was obtained by multiplying the percentage by the total cell numbers.
First, we compared the total cell numbers in the airway compartments and the
lymph node between the groups pre- and post-infection (Figure 3.2). There was no
difference in the number of cells between the groups in any of the three compartments
pre-infection, suggesting that in utero nicotine exposure is not associated with changes
in cell numbers at baseline (Figure 3.2a, c, e). However, post-infection cell numbers
increased significantly from the baseline only in the lung digest of the control group
(p=0.0411), and this number was significantly higher than that of the nicotine group
(Figure 3.2a, b). In the lung lavage samples and the lymph nodes, comparable cell
numbers were observed between the groups as well as pre- and post-infection (Figure
3.2c-f).
We then analyzed cells for markers of neutrophils (Ly6G+), resident alveolar
macrophages (CD11b-CD11c+), infiltrating monocytes (CD11b+Ly6G-), and
lymphocytes in different compartments to characterize subsets of total cells. Through
cytometric analysis, total cells were gated for granulocyte/monocyte population to
separate out lymphocytes and apoptotic cells, based on forward/side scatter
characteristics. Respective surface marker designations were used to obtain percent
values for neutrophils, resident alveolar macrophages, and infiltrating monocytes within
the gates. CD4, CD8, and CD19 cell populations were enumerated by gating for
lymphocyte population from the total cells. A representative flow cytometry plot is shown
in Figure 3.3, which depicts the gating scheme for neutrophils, resident macrophages,
and infiltrating monocytes in the lung digest from control (Top) and nicotine (Bottom)
groups.
Resident alveolar macrophages are the first-line defense against pathogens in
the airways, and they are characterized by a high expression of CD11c and low
expression of CD11b. When they fail to sufficiently control and maintain homeostasis
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against pathogens, circulating monocytes and neutrophils are recruited to the site of
infection, following cytokine/chemokine gradients, to supplement the initial burst of
inflammatory response (136). Infiltrating monocytes express a high level of CD11b, and
after they migrate to the lungs, their phenotype gradually begins to resemble that of the
resident macrophages (137). Neutrophils, another infiltrating cell type during an
infection, have a short lifespan but their survival is prolonged during an infection (136).
Release of neutrophils from the bone marrow pool further supplements their
accumulation in the lungs. This influx is critical for clearing bacteria and inducing
adaptive immune response (136). We defined neutrophil subset as a positive expression
of Ly6G on the cellular surface.
Both groups exhibited a significant increase in the number of neutrophils from
baseline in the post-infection lung digest (control: p<0.0001, nicotine: p=0.0184) (Figure
3.4a, b). However, post-infection neutrophil numbers were significantly higher in the
control group compared to nicotine group (p=0.0266, denoted) (Figure 3.4b). Similarly,
while baseline resident macrophage numbers were comparable, post-infection numbers
were significantly higher in the lung digest of the control group (p=0.0170, denoted)
(Figure 3.4c, d). Post-infection infiltration of monocytes was observed in the lung digest
of both groups, but unlike neutrophils, this influx was comparable between the treatment
groups (Figure 3.4e, f). Interestingly, these differences were not observed in the lung
lavage fluids (Figure 3.5a-f). Pre- and post-infection cell numbers remained similar for
neutrophils, resident macrophages, and infiltrating monocytes in both control and
nicotine groups, although there was a trend towards increased post-infection influx of
neutrophils in the nicotine group (p=0.056) (Figure 3.5a, b). No significant differences in
the number of cells were observed between the groups.
Next, we analyzed cells of the adaptive immunity, CD4+ and CD8+ T lymphocyte
and B lymphocyte characteristics in each compartment. B lymphocytes were
characterized by the expression of CD19. T and B lymphocytes have a delayed
response compared to innate immune cells and become effective 5-7 days post-infection
(138). This is because dendritic cells are needed to first transport antigens into draining
lymph nodes and activate naïve T cells that are specific to a particular antigen.
Subsequently, antigen-specific T cells are selected, differentiated, proliferated, and
travel back to the inflamed tissue to remove pathogens or remain in the lymph nodes to
activate B cells. Therefore, we compared subsets of lymphocytes in the lung tissue and
lymph nodes on post-infection day 5.
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Nicotine groups displayed a significant increase in the number of CD4+ and
CD8+ T cells in the lung digest post-infection (p=0.0004 and p=0.0273 for CD4+ and
CD8+ T lymphocytes, respectively) compared to baseline (Figure 3.6a-d). However, both
pre- and post-infection CD4+ and CD8 T cell numbers were similar to those of control
group. Interestingly, the control group had comparable pre- and post-infection CD4+ and
CD8+ T cell numbers. On the contrary, the nicotine group had a significantly lower
number of B lymphocytes post-infection (p=0.0482) from baseline, and this number was
significantly lower than that of the control group (p=0.0109, denoted) (Figure 3.6e, f).
Neither group nor time after infection had an impact on CD4+ T lymphocyte counts in the
lymph nodes (Figure 3.7a, b). However, a significant increase in the CD8+ T
lymphocytes was noted in the lymph node of control group, compared to baseline
(p=0.0235) (Figure 3.7c, d). Unlike in the lung digest, post-infection B lymphocytes of the
nicotine group increased significantly compared to the baseline (p=0.0247) as well as
compared to control in the lymph nodes (p=0.0386, denoted) (Figure 3.7e, f).
Overall, this data shows that the baseline cell numbers were not affected by in
utero nicotine exposure in any of the three compartments analyzed. However, some key
differences in the immune response were observed upon Pseudomonal lung infection.
Although robust neutrophil influx was observed post-infection in both groups, this was
less pronounced in the nicotine group. Additionally, a significant reduction in the number
of B cells in the lung interstitium but a significant elevation in the lymph nodes in the
nicotine group suggests a potential defect in migration and/or proliferation of B
lymphocytes, due to in utero nicotine exposure.
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Characteristics of cell composition and disposition
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Figure 3.2 Pre- and post-infection cell counts in the lung digest, lung lavage, and lymph nodes.
In utero nicotine exposed mice were generated from pregnant mice fed with saccharin- or
nicotine-dissolved water throughout pregnancy and humanely killed at 4-6 weeks of age before
and after intratracheal infection with P. aeruginosa. Immune cells were quantified by flow
cytometry in (a-b) lung digest, (c-d) lung lavage fluid, and (e-f) lymph node. Data represents the
mean ± SD, and statistical significance is indicated for p value < 0.05 (*) between the groups. (*)
denotes significance between groups. Data was analyzed by two-way ANOVA for comparison of
the groups and t-test for comparison of pre- and post-infection

46

Figure 3.3 Lung parenchyma cell analysis by flow cytometry. On post-infection day 5, lungs were harvested from mice exposed to saccharin (Top)
or nicotine (Bottom) developmentally. Single cell suspension was created by incubating lung tissue with collagenase and DNase. Cells were
stained with fluorescently labeled antibodies to determine surface marker expression. Initially, cells were gated to isolate granulocyte/monocyte
population. Subsequently, neutrophil (Ly6G+), resident macrophage (CD11b-CD11c+), and infiltrating monocyte (CD11b+Ly6G-) populations were
analyzed by their respective surface marker expressions. SSC, side scatter; FSC, forward scatter.
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Figure 3.4 Pre- and post-infection neutrophil, resident macrophages, and infiltrating monocytes
in lung digest. In utero nicotine exposed mice were generated from pregnant mice fed with
saccharin- or nicotine-dissolved water throughout pregnancy and humanely killed before and after
intratracheal infection with P. aeruginosa. Immune cells were quantified by flow cytometry in the
lung digest for markers of (a-b) neutrophils (Ly6G+), (c-d) resident macrophages (CD11bCD11c+), and (e-f) infiltrating monocytes (CD11b+Ly6G-). Data represents the mean ± SD, and
statistical significance is indicated for p value < 0.05 (*). (*) denotes significance between groups.
Data was analyzed by two-way ANOVA for comparison of the groups and t-test for comparison of
pre- and post-infection.
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Figure 3.5 Pre- and post-infection neutrophil, resident macrophages, and infiltrating monocytes
in lung lavage. In utero nicotine exposed mice were generated from pregnant mice fed with
saccharin- or nicotine-dissolved water throughout pregnancy and humanely killed before and after
intratracheal infection with P. aeruginosa. Immune cells were quantified by flow cytometry in the
lung lavage samples for markers of (a-b) neutrophils (Ly6G+), (c-d) resident macrophages
(CD11b-CD11c+), and (e-f) infiltrating monocytes (CD11b+Ly6G-). Data represents the mean ±
SD. Data was analyzed by two-way ANOVA for comparison of the groups and t-test for
comparison of pre- and post-infection. Differences were not statistically significant.
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Figure 3.6 Pre- and post-infection T lymphocytes and B lymphocytes in lung digest. In utero
nicotine exposed mice were generated from pregnant mice fed with saccharin- or nicotinedissolved water throughout pregnancy and humanely killed before and after intratracheal infection
with P. aeruginosa. Immune cells were quantified by flow cytometry in the lung digest for markers
of (a-b) CD4+ T lymphocytes, (c-d) CD8+ T lymphocytes, and (e-f) B lymphocytes (CD19+). Data
represents the mean ± SD, and statistical significance is indicated for p value < 0.05 (*). (*)
denotes significance between groups. Data was analyzed by two-way ANOVA for comparison of
the groups and t-test for comparison of pre- and post-infection.
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Figure 3.7 Pre- and post-infection T lymphocytes and B lymphocytes in lymph node. In utero
nicotine exposed mice were generated from pregnant mice fed with saccharin- or nicotinedissolved water throughout pregnancy and humanely killed before and after intratracheal infection
with P. aeruginosa. Immune cells were quantified by flow cytometry in the lymph nodes for
markers of (a-b) CD4+ T lymphocytes, (c-d) CD8+ T lymphocytes, and (e-f) B lymphocytes
(CD19+). Data represents the mean ± SD, and statistical significance is indicated for p value <
0.05 (*). (*) denotes significance between groups. Data was analyzed by two-way ANOVA for
comparison of the groups and t-test for comparison of pre- and post-infection.
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Cytokine production in the lung lavage fluid of P. aeruginosa infected mice
Various pro- and anti-inflammatory cytokines are produced in response to an
infection, and the balance of these mediators is crucial in amplifying or suppressing the
immune response at a proper timing. IL-6, IFNγ, TNFα, and IL-12 are secreted from M1
polarized macrophages in response to an infection and IL-12 also promotes
differentiation of T cells into the Th1 subset, potentiating the pro-inflammatory response.
On the contrary, IL-10 is secreted by Th2 cells to regulate exaggerated inflammatory
responses and to reduce tissue damage. Therefore, we assessed levels of IL-6, IL-10,
MCP-1, IFNγ, TNFα, and IL-12p70 in the lung lavage fluids of mice 5 days post-infection
to compare cytokine milieu in response to an infection.
The most prominent difference was observed in MCP-1 level, which is a
chemoattractant protein for monocytes. MCP-1 is produced in high levels during
infection by both immune and non-immune cells. As the name implies, it promotes
recruitment of monocytes to the inflamed tissue and also attract neutrophils during
severe infection (139). We observed higher concentrations of MCP-1 in the lung lavage
fluid of the nicotine group in a single experiment and it remained elevated when results
are pooled from 3 separate cohorts. The pro-inflammatory cytokines IL-6 and TNFα were
additionally found to be increased from pooled data while IL-10, IFNγ, and IL-12 levels
were not different between groups (Figure 3.8a, b).
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Figure 3.8 Cytokine concentrations in the lung lavage fluid of mice after P. aeruginosa infection.
In utero nicotine exposed mice were generated from pregnant mice fed with saccharin- or
nicotine-dissolved water throughout pregnancy and humanely killed before and after intratracheal
infection with P. aeruginosa. On post-infection Day 5, lung lavage samples were collected and
cytokine levels were measured by CBA. Figure a) describes one cohort and figure b) is pooled
data from 3 separate experiments. Data represents the mean ± SD, and statistical significance is
indicated for p value < 0.05 (*) and < 0.0001 (****). Data was analyzed by multiple t-test.
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Cytokine production from macrophage cell culture
In order to assess macrophage cytokine profile at baseline and upon M1 or M2
polarized states, we harvested murine bone marrow cells and stimulated them ex vivo.
Bone marrow cells were obtained from mice exposed to saccharin (control) or nicotine
developmentally and differentiated into macrophages for 7 days ex vivo, as described in
Methods. When fully differentiated, bone marrow-derived macrophages were stimulated
with LPS and IFNγ or IL-4/13 to polarize them into M1 or M2 macrophages, respectively.
Cytokine concentrations in the supernatants were measured to assess cellular response
to stimulation and polarization. Cytokine levels were comparable between the two
groups without any stimulation (media only). However, several differences were noted
between control and nicotine groups upon stimulation and polarization. First, production
of all cytokines were elevated upon polarization to M1, except for IL-10, which is an antiinflammatory cytokine produced mainly by M2 macrophages (Figure 3.9a, b). This was
true for both control and nicotine groups, and the nicotine group was associated with
higher production of IL-10 compared to both media treatment and the M1 polarized
control group. IL-10 levels were elevated upon M2 polarization for both groups and the
levels were comparable between the two groups (Figure 3.9a, c). The most prominent
finding was the production of IFNγ, which was significantly increased upon M1
polarization, but not upon M2 polarization, in both groups (Figure 3.9a-c). One caveat is
that IFNγ was added to the culture in M1 polarized cells but not M2 polarized cells.
However, significantly elevated production of IFNγ in the control group compared to the
nicotine group is noteworthy (Figure 3.9b). Similarly, increased TNFα levels were
observed upon M1 polarization for both groups (Figure 3.9b), but interestingly this was
comparable to M2 polarized macrophages (Figure 3.9c). The nicotine group was
associated with significant reduction in production of IL-6 and MCP-1 compared to
control group for both M1 and M2 polarizations (Figure 3.9b, c). This is reverse of what
was observed from lung lavage fluids of mice infected with P. aeruginosa (Figure 3.8b).
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Figure 3.9 Cytokine production in the supernatants of ex vivo BMDM. In utero nicotine exposed
mice were generated from pregnant mice fed with saccharin- or nicotine-dissolved water
throughout pregnancy. Bone marrow-derived macrophages (BMDM) were stimulated with LPS
and treated with IFNγ or IL-4/13 for M1 or M2 polarization, respectively. After overnight
incubation, supernatants were collected to determine cytokine concentrations by CBA. Figures
describe a) baseline cytokine levels, b) cytokine levels when polarized to M1, and c) cytokine
levels when polarized to M2. Data represents the mean ± SD, and statistical significance is
indicated for p value < 0.05 (*), < 0.01 (**), < 0.001 (***), and < 0.0001 (****). Data was analyzed
by two-way ANOVA.
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Arginase activity
A previous study reported that in utero nicotine exposure shifts the resting state
AM into an alternative phenotype (104). We utilized BMDM from control and nicotine
mice to measure arginase activity as a marker of alternative activation when stimulated
with LPS ex vivo. Cells were treated with media only, IFNγ+LPS to induce M1
polarization, or IL-4/13+LPS to induce M2 polarization. Cell lysates were obtained to
assess arginase activity. First, we assessed cell viability with and without stimulation to
determine whether developmental nicotine exposure affects this parameter. There was
no difference in cell viability between control and nicotine groups when polarized into M1
or M2 (Figure 3.10a). Additionally, protein concentrations were comparable between the
groups as well as across the cytokine treatments (Figure 3.10b). We found significantly
increased arginase activity in cells polarized to the M2 phenotype in both control and
nicotine groups, and this increase was more pronounced in the nicotine group
(p=0.0588, denoted) (Figure 3.10c). Low levels of arginase activity were detected in cells
treated with media only as well as M1 polarized cells, and this was similar between
control and nicotine groups (Figure 3.10c). When normalized to protein concentration,
increased arginase activity in M2 polarized cells of nicotine group was less pronounced,
resulting in a similar arginase activity between M2 polarized cells of control and nicotine
groups (Figure 3.10d). Similarly, the two groups were comparable when arginase activity
was normalized to cell counts (Figure 3.10e).

56

C e ll c o u n t (c e lls /m L )

C e ll v ia b ilit y
6´10

05

4´10

05

2´10

05

C o n tro l
N ic o tin e

P
L
+
3
IL

4

IF

/1

N

M

+

e

L

d

P

ia

S

S

0

a)

P r o t e in c o n c e n t r a t io n

C o n c e n t r a t io n (u g /m l)

300

C o n tro l
N ic o tin e
200

100

P
L
+
3
IL

4

IF

/1

N

M

+

e

L

d

P

ia

S

S

0

b)

R a w A r g in a s e a c t iv it y

( U p e r c e ll/m L )

A r g in a s e A c tiv ity

25

*

20
15
10
5

P

S

3
/1
4
IL

IF

N

+

+

L

L

P

ia
d
e
M

c)

S

0

57

C o n tro l
N ic o tin e

A r g in a s e /P r o t e in

A r g in a s e A c tiv ity

( u n it s p e r m g p r o t e in )

0 .1 0

C o n tro l
N ic o tin e

0 .0 8
0 .0 6
0 .0 4
0 .0 2

P
L
+
3
IL

4

IF

/1

N

M

+

e

L

d

P

ia

S

S

0 .0 0

d)

0 .6

C o n tro l
N ic o tin e
0 .4

0 .2

P

S

L

P

3
/1
4
IL

IF

N

+

+

L

d
e
M

S

0 .0

ia

A r g in a s e A c tiv it y ( x 1 0 ^

-4

)

A r g in a s e /C e ll

e)
Figure 3.10 Arginase activity at baseline and upon M1 and M2 polarization. In utero nicotine
exposed mice were generated from pregnant mice fed with saccharin- or nicotine-dissolved water
throughout pregnancy. Bone marrow-derived macrophages (BMDM) were stimulated with LPS
and treated with IFNγ or IL-4/13 for M1 or M2 polarization, respectively. After overnight
incubation, cell lysates were collected to measure arginase activity. Figures describe a) cell
viability as measured using Trypan blue staining, b) protein concentration, c) raw arginase
activity, d) arginase activity normalized to protein concentration, and e) arginase activity
normalized to cell numbers. Data represents the mean ± SD, and statistical significance is
indicated for p value < 0.05 (*). Data was analyzed by multiple t-test.
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Human Tracheal Aspirate Sample Processing
In our murine model, animals were allowed to age for 4-6 weeks prior to
performing various experiments described above. This is equivalent to approximately
young adult age in humans, at which nicotine effects mediated during the critical periods
of fetal development are likely to be less pronounced due to post-birth factors (140). To
better understand the impact of in utero nicotine exposure when it is most pronounced
and to investigate its impact in humans, we designed a clinical study, recruiting neonates
from the University of Kentucky Medical Center born to mothers who 1) did not smoke
during pregnancy, 2) smoked throughout pregnancy, or 3) used NRT during pregnancy.
The study was designed to characterize and compare alveolar macrophage gene
expression obtained from neonates who are placed on a ventilator in the NICU. As a
standard care measure, tracheal aspirate samples are suctioned to maintain patency of
the ventilation tubes and discarded immediately. For this study, we attempted to collect
these samples and transfer them to the laboratory to purify alveolar macrophages and
isolate RNA 1) immediately upon purification and 2) after stimulating with LPS to
determine macrophage response.
Prior to enrolling patients, we performed preliminary work to establish successful
RNA isolation techniques with human samples. Approximately 1 mL volume was
recovered from tracheal aspirate samples obtained from each patient in the NICU, and
samples were processed according to the protocol described in the Methods section.
Quality and quantity of isolated RNA were determined using the UV spectrophotometer,
and the A260/A280 ratio of 1.8-2.1 was used as a target of quality. First, the entire sample
was purified, immediately upon receiving, to isolate RNA, using 350 µL or 1 mL of
TRizol® reagent. When low volume of TRizol® was used, A260/A280 ratio did not fall in the
desired range, suggesting impurities and unreliable results. Higher volume of TRizol® led
to successful isolation, and this was true only with 2x106 cells/mL (Table 2a). Next, we
cultured purified alveolar macrophages and stimulated them with LPS 10 ng/mL prior to
isolating RNA. After 6 h incubation, cells were collected and RNA was isolated, following
the same procedure and using 1 mL TRizol®. We observed that A260/A280 ratio fell within
the desired range from these samples (Table 2b). Overall, the results suggest that
successful RNA isolation can be achieved by using the described methods and using
neonatal tracheal aspirate samples, and cell number and reagent volumes are important
determinants of acceptable RNA quality and quantity. This preliminary data sets the
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groundwork for our proposed clinical study of investigating the alveolar macrophage
gene expression profile in neonates exposed to in utero nicotine via various methods.
a)

b)

Sample number

Cell counts

A260/A280 ratio

Treatment

A260/A280 ratio

1

1.5x106 cells/mL

1.16

Media

1.8

2

1x106 cells/mL

1.32

Media

1.47

3

2x106 cells/mL

1.82

LPS 10 ng/mL

1.71

4

1x104 cells/mL

1.49

LPS 10 ng/mL

1.86

Table 2.1 RNA isolation results from clinical tracheal aspirate samples. Samples were collected
from neonates placed on a ventilator and processed to purify alveolar macrophages. A) RNA
isolated immediately after obtaining samples from patients. Samples 1 and 2 were saved in 350
µL TRizol and samples 3 and 4 were saved in 1 mL TRizol. B) RNA isolated from cells cultured in
the presence or absence of LPS.
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Chapter 4. Conclusion

Despite known perinatal health risks of smoking during pregnancy, many
pregnant smokers fail to achieve complete cessation (7). Although NRTs are considered
first-line treatment options during pregnancy, there is paucity of data to suggest NRT is
safe and effective during pregnancy (3). Furthermore, many recent studies observed that
the physiological effects of nicotine are not only limited to the nervous system but can
modulate functions of non-neuronal cells, (4, 107). This is mediated through the nicotinic
acetylcholine receptors (nAChR) present in non-neuronal cells, including the immune
cells. Investigation of the role of nAChR is an active area of research, and so far it has
been observed that stimulation of nAChR can dampen inflammatory responses from
macrophages and stimulate proliferation of T cells. Most of what is known regarding the
effect of nicotine on the immune system suggests that nicotine is an anti-inflammatory
molecule, as suggested by suppressed secretion of inflammatory mediators (99, 100,
109). This is an important area of research particularly for smokers who use NRT under
the notion that there is no harm to their health and regard NRT as a safer option.
Moreover, this introduces concerns for pregnant smokers whose fetuses are exposed to
nicotine through the placental barrier with the potential to modulate cells directly as well
as indirectly through developmental alterations. Therefore, we sought to investigate the
effect of in utero nicotine exposure on the immune response to P. aeruginosa lung
infection as well as ex vivo LPS stimulation.
The infection model we have employed in this study is an excellent method in
assessing chronic lung infection commonly seen in smokers. As discussed in this thesis,
smokers have an increased susceptibility to infection, and many of them suffer from
chronic inflammation of the lungs and repetitive respiratory infections as a result of
damages induced by cigarette smoke (73). By administering P. aeruginosa-laden
agarose beads intratracheally, we can assess the immune response against bacteria in
orchestrating the balance between pro- and anti-inflammatory responses and monitor
the overall clinical status, such as animal weight, over time. Any alterations of the
immune cell functions, due to developmental nicotine exposure, that result in an
inadequate control of the infection is manifested by poor clinical status, as this
parameter is commonly used to determine the response to an infection (74, 92, 134).
This model is extensively used in other investigations associated with chronic lung
infection, such as in cystic fibrosis (134).
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In this study, we hypothesized that in utero nicotine exposure would alter immune
cell disposition and function in response to P. aeruginosa lung infection. We found that
the nicotine group had a worsened clinical outcome, as measured by weight-loss over
time post-infection. Additionally several differences were observed with regard to
immune cell disposition and cytokine profile in the lung tissue, lung lavage fluid, and
lymph nodes post-infection. However, these results are not conclusive but rather
preliminary. The work accomplished to this point sets the groundwork for addressing our
hypothesis but does not answer it. Importantly, findings from our study appear to
contradict some of what is known in the current literature. For example, maternal
smoking or nicotine exposure is generally known to cause low birthweight, which was
not observed in our study. We had a total of 62 offspring mice (31 mice in each group)
generated from mice fed with saccharin- or nicotine-dissolved water, and their baseline
weights prior to infection were not different. This may be explained by the time elapsed
between birth and the day of infection, which was approximately 4-6 weeks. It is possible
that weight differences, if any, may have been minimized during postnatal development.
Due to the cannibalistic behavior of the mothers, neonatal mice could not be
manipulated from the cages prior to weaning. However, post-infection weight changes
suggest that in utero nicotine exposure may impact the overall clinical outcome.
Our study did not find any baseline differences in the number of cell
subpopulations. Cell numbers were comparable to those of control group for all subsets
analyzed, and differences were observed only in post-infection numbers, including
pronounced dampened neutrophil influx, increased CD4 and CD8 cell numbers in lung
tissue, and increased B cells in the lymph nodes. This is similar to the results of other
studies investigating the effects of prenatal nicotine exposure on neonatal and adult
animal immune cell populations (141, 142). Despite similar baseline numbers, one study
observed that CD8+ T-lymphocyte activity was significantly reduced when exposed to
cigarette smoke developmentally, which suggests that there is an impact of prenatal
cigarette smoke exposure on functional capacity of CD8+ T cells (141). We did not
assess this parameter for CD8+ T cells, but the impact observed on the cytokine profile
from in vivo and ex vivo studies may support the notion of altered function. In our study,
in utero nicotine exposure was associated with significantly increased production of the
inflammatory cytokines IL-6, MCP-1, and TNFα on day 5 post-infection in the lung
lavage fluid. Interestingly, the opposite occurred during our ex vivo experiments. IL-6
and MCP-1 levels were higher in the control group, and additionally IFNγ concentrations
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were significantly elevated in the control group. One possible explanation for this
observation is the difference in time when the cytokine levels were measured. M2
polarization induced by developmental nicotine exposure suppresses inflammatory
response 6 hours after stimulation with LPS, as observed with our ex vivo data. This
initial response perhaps leads to delayed resolution and prolonged inflammation, which
results in increased production of pro-inflammatory cytokines 5 days after P. aeruginosa
infection, as demonstrated in vivo.
Fetal and neonatal T cell immunity is known to be unbalanced, with a bias
towards Th2 cells, which increases neonatal susceptibility to infectious diseases
compared to adults (143). This does not necessarily indicate that neonates are born with
immunodeficiency, as they are able to generate effective immune responses, such as
induction of Th1 cells upon stimulation with antigen. Th1 cell apoptosis was observed,
however, when cells were re-challenged with the antigen while Th2 cells mediated a
secondary response. Subsequent research to understand specific mechanisms
underlying this phenomenon suggests that IL-4 produced by Th2 cells mediates Th1 cell
apoptosis (143). Development of the immune system continues to occur postnatally, and
the fetal and neonatal period is considered a critical timeframe that requires sequential
stimulation to induce differentiation, proliferation, and degeneration (143). Unbalanced
Th1/Th2 stimulation in fetuses and neonates is, therefore, in its transitory period and will
ultimately adapt to the environment and establish functional capacities during postnatal
developmental periods when stimulated appropriately.
Our study and previous studies report that in utero nicotine exposure is
associated with a shift towards a Th2 response, and towards an M2 macrophage
response which mediates regulation of inflammation (100, 104). We observed increased
activity of arginase in M2 polarized cells in mice developmentally exposed to nicotine
compared to the control group, although no differences were observed at baseline.
Wongtrakool et al. reported an increased number of macrophages expressing arginase1, as well as Ym1 and fibronectin, when exposed to nicotine in utero (104). Furthermore,
cytokine profiles in the lung were associated with Th2 responses, as suggested by
increased TGFβ1 and IL-13 mRNA expression. Currently available literature generally
suggests biased Th2 cell responses in part due to Th1 cell apoptosis. It could be
speculated that developmental stimulation of nAChR affects apoptosis/survival signal
specific to Th cell phenotypes and potentiate a Th2 response, which ultimately interferes
with establishing a well-balance Th1/Th2 system. One such example is demonstrated
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through α7 nAChR, whose pro-survival role was demonstrated in M2 macrophages and
not in M1 macrophages (144). In this study, activation of the STAT3 signaling pathway
was observed upon α7 nAChR stimulation, which is known to be involved in the
regulation of cell growth and survival. This observation, however, was specific to M2
polarized bone marrow-derived macrophages only (144). Therefore, it is plausible that
stimulation of α7 nAChR, and perhaps other nAChRs, during development via maternal
use of nicotine containing products can modify survival of immune cells and render the
immune tone set at birth.
Epigenetic regulation of immune cell development is another possible
mechanism through which in utero nicotine modulates immune cell disposition and
function. Epigenetic modifications involve post-transcriptional acetylation and
methylation of histone proteins that can result in different cell phenotypes without
affecting DNA sequence (145). Studies report altered histone modification and
methylation in the brain and lungs of mice exposed to nicotine developmentally, and
these patterns were similar to those in individuals with behavioral alterations, including
drug addiction (145). Intrauterine exposure to cigarette smoke was also shown to affect
the DNA methylation pattern which is negatively associated with neuronal content in the
fetal brain (146). Epigenetic control of immune cell differentiation is best characterized in
T cells. For example, demethylation of the IFNγ gene promoter occurs in the Th1 cell
lineage while demethylation of the IL-4 gene occurs in the Th2 cell lineage.
Concomitantly in Th2 cells, DNA methylation of the IFNγ gene occurs, which ultimately
silences the expression of Th1-associated genes when Th2-associated genes are
expressed (147). Prenatal cigarette smoke exposure is known to be associated with
increased methylation of peripheral blood genes (148). Patil et al. analyzed the
association between prenatal cigarette smoke exposure and DNA methylation pattern
and observed that there is an interaction between the pattern of methylation and
maternal smoking as well as a gene variant for IL-13 that, together, affect lung function
(149). Although limited at this time, the influence of maternal cigarette smoking on
epigenetic changes in newborns is a growing area of study, and associations between
altered epigenetic patterns and health outcomes can lead to a better understanding of
predisposition for health risks.
The result of developmental nicotine exposure on the overall immune network of
an individual is complex and multi-layered. First, the effects of nicotine directly on
immune cells introduce a potential effect. Second, the effects of in utero nicotine
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exposure on development of the immune cells and response is another major issue that
is yet to be fully understood. One other aspect of in utero nicotine exposure influencing
the immune network is the cholinergic regulation of the immune system. There is
evidence that vagus nerve stimulation results in an inhibition of peripheral inflammatory
cytokine production by splenocytes, and that this is mediated through α7 nAChR. One
such example is the exaggerated inflammatory response, manifested by greater tissue
damage, in the models of colitis, septic shock, and pancreatitis in α7 nAChR knock-out
mice. This has become known as the ‘cholinergic anti-inflammatory pathway’ (Reviewed
in 128). Although the study of prenatal cigarette smoke and nicotine exposure on brain
development and neurobehavioral outcomes in the offspring have been active areas of
research for many years, how this impacts the network of immune regulation is rather
novel, especially when referring to the interconnected function between neuronal and
non-neuronal cholinergic systems. This study targets the issue from one direction, from
the perspective of the immune cells. Consistent with other studies, findings from our
preliminary results suggest that in utero nicotine exposure leads to an unbalanced
macrophage tone, with a shift in macrophage function towards an anti-inflammatory M2
phenotype. This could potentially affect the development of the reflex network of
neuronal regulation of inflammation by changing the milieu of the cytokine profile in the
local environment. Furthermore, hyperstimulation of the nAChR, out of sequence, may
generate under- or over-expressed cholinergic anti-inflammatory pathways. Future
studies addressing the impact of developmental nicotine exposure on the neuronal
stimulation of the immune network, and whether this results in an aberrant immune
reflex, will additionally address the overall impact in an individual’s baseline immune
tone and response.
There are several limitations in this study. First, our animal model had
considerable variation in regard to the level of infection between and within the cohorts.
We utilized intratracheal infection with P. aeruginosa embedded in agarose beads to
ensure a chronic, stable infection. This model had been previously established and
widely utilized by other investigators for the assessment of P. aeruginosa lung infection
(134, 150, 151). Although we confirmed the amount of bacteria for inoculation prior to
infection, it is difficult to know if all mice received the same amount of bacteria. This may
explain the intra-experiment variability we observed with post-infection weight loss as
well as other data. If mice died early prior to analysis, this resulted in unbalanced sample
sizes, which may be skewing some of the data. Additionally, preparation of P.
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aeruginosa embedded beads requires adequate bacterial growth and production of
beads in various sizes. This is a difficult task and requires timely coordination of two
separate procedures. Moreover, reproduction of same sized beads is unlikely between
experiments, increasing inter-experiment variability. In order to reduce these variabilities,
we modified our infection model by separately preparing bacterial culture and sterile
agarose beads and mixing them prior to infection. This would allow us to keep a stock of
beads that could be used for several experiments, reducing the inter-experiment
variability. We ensured that bacteria were grown to late log phase and determined
dilutions of stock beads and the amount of bacteria sufficient to induce a stable infection
when mixed together. However, alternate method resulted in a similar level of intra- and
inter-experiment variability and required higher number of bacteria to induce similar level
of post-infection weight loss we had observed with our initial experiments.
The amount of maternal nicotine ingestion may affect the extent of
developmental alterations in the fetus, and classification or sub-analysis of offspring by
the amount of in utero exposure may provide a greater understanding of dosedependent effects. We utilized C57BL/6 mice with a GFP tag on nicotinic receptors that
were bred in-house. Mice were fed with either saccharin dissolved or nicotine dissolved
water ad libitum before and throughout pregnancy to generate in utero nicotine exposed
offspring. This is a well-established model for experimental administration of nicotine.
Other methodologies include parenteral nicotine injection several times a day or
installing an osmotic minipump (152). However, these alternative methods have several
disadvantages, such as stress of daily injections over a long-time period as well as the
expense for installing and replacing the pumps, depending on the timeframe needed for
the study. In study by Rowell et al, mice weighing 18-22g were fed ad libitum with either
plain water or nicotine solutions (20-100 µg/mL) for up to 4 weeks to address the validity
of such a methodology as an investigational model for chronic nicotine administration.
Although reduction in drinking behavior was observed when nicotine concentrations
were greater than 20 µg/mL, this behavior was comparable to the control group even at
nicotine concentrations of 100 µg/mL when saccharin was added to the solution.
Gradual increase in nicotine amount also led to a normal fluid intake behavior. Other
studies have utilized 200 µg/mL and have seen biochemical efficacy as well as
neurodevelopmental alterations without significant effects on perinatal outcomes, such
as maternal and offspring weights or fluid intake (153, 154). In our study, we were
unable to assess nicotine, or practically cotinine, levels in mothers or the offspring after
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delivery due to cannibalistic behaviors in nurturing mothers upon manipulation of animal
cages or the offspring. In order to accurately measure and control the amount of nicotine
administered, other modes of administration could be considered, such as daily injection
or implantation of pumps. However, these methods are invasive and require several
manipulations of pregnant mice, which would be a stressful event during the critical
periods. For future studies, sacrifice of neonatal mice for determination of cotinine levels
by ELISA can be considered to maintain the sample size for post-infection analyses.
We attempted to compare gene expression in neonates born to non-smoking
mothers, to mothers either using NRT or who continued to smoke throughout pregnancy
and correlate changes in gene expression patterns to the mode of nicotine exposure.
Despite IRB approval and initiation of the clinical study, we were unable to recruit
patients, resulting in obtaining samples for practice trials only. However, validation of the
experimental methods has been successfully accomplished, and continued recruitment
of study candidates is ongoing. Once a sufficient number of patients is recruited to
statistically analyze the results, we can make a correlation between in utero nicotine
exposure and changes in macrophage gene expression that can guide future study
directions. For example, any abnormal expression can be targeted and explored for
underlying mechanisms involved in its expression and the consequences from observed
changes.
This study provides preliminary data to understand potential research areas and
several preliminary findings noted from the study highlight that in utero nicotine exposure
leads to changes in immune response against P. aeruginosa lung infection. Any robust
observation in the future will positively impact current smoking cessation guidelines for
pregnant women by providing safety data that is currently lacking. Moreover, the clinical
study in neonates will enable correlation of macrophage gene expression changes
mediated by different modes of nicotine exposure and provide a better understanding of
individual’s predisposition for infection.
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Appendices

A. Appendix I: List of genes for gene expression analysis

Well
A1
A2
A3
A4
A5
A6
A7
A8
A9
A10
A11
A12
A13
A14
A15
A16
A17
A18
A19
A20
A21
A22
A23
A24
B1
B2
B3
B4
B5
B6
B7
B8
B9
B10

Gene
CD86
CD64/CD64
ITGAM
CD14
CD68
CD23/FCER2
CD40
STAT1
SOCS3
SLAMF1
RNA18S5
TNF
IL6
IL12B
IL1B
IL10
TGFB1
IL12A
IL8/CXCL8
IL23A

IL4RA
IL27RA
HLA-DRA
MARCO
CCL17
CCR2
TREM2
CCL22
CCL18
NOS2
RETNLB
ARG1
PPARG
IKBKB

Fisher #
Hs01567026_m1
Hs00417598_m1
Hs00167304_m1
Hs02621496_s1
Hs02836816_g1
Hs00233627_m1
Hs01002915_g1
Hs01013996_m1
Hs02330328_s1
Hs00234149_m1
manufacturing control (housekeeping gene)
Hs00174128_m1
Hs00174131_m1
Hs01011518_m1
Hs01555410_m1
Hs00961622_m1
Hs00998133_m1
Hs01073447_m1
Hs00174103_m1
Hs00372324_m1
Hs00965056_m1
Hs00945029_m1
Hs00219575_m1
Hs00198937_m1
Hs00171074_m1
Hs00704702_s1
Hs00219132_m1
Hs01574247_m1
Hs00268113_m1
Hs01075529_m1
Hs00395669_m1
Hs00163660_m1
Hs01115513_m1
Hs01559460_m1
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B11
B12
B13
B14
B15
B16
B17
B18
B19
B20
B21
B22
B23

ARG2
IDO1
IRF1
MRC1/CD206
NLRP1
CASP1
MAP1LC3B
AKT1
PCNA
ATG5
MTOR
GCN2/EIF2AK4
GAPDH
CCND1/cyclin

B24 D1

Hs00982833_m1
Hs00984148_m1
Hs00971965_m1
Hs00267207_m1
Hs00248187_m1
Hs00354836_m1
Hs00797944_s1
Hs00178289_m1
Hs00427214_g1
Hs00169468_m1
Hs00234508_m1
Hs01010957_m1
Hs02786624_g1
Hs00765553_m1
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B. Appendix II: Survey Questionnaire and Data Collection Form

Impact of in utero nicotine exposure on neonatal ex vivo macrophage responses study
Survey Questionnaire
1. Are you a present/former smoker?
¨ Yes
¨ Yes, e-cigarette use
¨ No
2. If answered Yes in #1, how often do you usually smoke cigarettes (Before you became
pregnant)?
¨ Every day
¨ On most days
¨ Less than most days
3. What was your smoking status during pregnancy? Check all that apply (Please provide in
detail on Page 2)
¨ Every day/on most days
¨ Smoking cessation aids: Nicotine replacement therapy (NRT)
¨ Did not smoke at all/Smoked occasionally
¨ Never smoked
¨ Other: Please specify__________________
4. If you smoked during pregnancy, daily number of cigarettes smoked: ______________
Please indicate “0” if you did not smoke during pregnancy (Please fill out Page 2 for
details)
5. If you smoked/used nicotine replacement therapy (NRT) during pregnancy, which of the
following best describes you?
¨ Smoked cigarettes only
¨ Tried using nicotine replacement therapy (NRT) but mostly smoked cigarettes
¨ Smoked cigarettes and used nicotine replacement therapy (NRT) equally
¨ Used nicotine replacement therapy (NRT) more often/consistently than smoking
¨ Used nicotine replacement therapy (NRT) only
¨ Not sure
¨ N/A
6. Approximately how many cigarettes have you smoked in the last week?
_____________________________
7. If you used nicotine replacement therapy (NRT) during pregnancy at any point, what
type of aid(s) did you use? Check all that apply.
¨ Nicotine patch
¨ Nicotine gum
¨ Nicotine inhaler
¨ Nicotine lozenge
¨ Nicotine spray

70

8. When was the last time you smoked/used nicotine replacement therapy (NRT)? Please
indicated “N/A” if you never smoked during pregnancy
¨ 1-2 days ago
¨ 3-4 days ago
¨ 5-6 days ago
¨ More than 1 week ago
¨ N/A
Trimester/Month

Approximate # of Cigarettes/day

1st Trimester (1)

1st Trimester (2)

1st Trimester (3)

2nd Trimester (4)

2nd Trimester (5)

2nd Trimester (6)

3rd Trimester (7)
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Nicotine Replacement Therapy
(NRT)

3rd Trimester (8)

3rd Trimester (9)

•

Please indicate the type of nicotine exposure in detail (smoking, e-cigarette, form of
NRT) and describe as appropriate
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Nicotine Study Data Collection Form

Date: _______________________________
Patient ID (Mother/Baby’s MR#) : ___________________________
Mother’s Age/DOB: ____________________
Gestational Age at Birth: ______________________
Gender of infant:

M

F

Race: _______________________________
Study ID: ______________________

Samples Collected:
Date Collected

Age (Days)

Time Collected

Time Processed

Notes

____________

____________

____________

_____________

__________________________

____________

____________

____________

_____________

__________________________

____________

____________

____________

_____________

__________________________

____________

____________

____________

_____________

__________________________

____________

____________

____________

_____________

__________________________
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Mode of nicotine exposure (circle one):

Smoking

NRT

BOTH/OTHER

If BOTH/OTHER, specify: _________________________________

Comorbidities: ___________________________________________________________________

Procedures
Type of Procedure

Date

________________________

__________________________

________________________

__________________________

________________________

__________________________

Any active infection (circle one):

YES

NO

Immune altering underlying condition (circle one):
Immune altering medication (circle one):

YES

YES

NO

NO

Medications
Drug

Start Date

Stop Date

Notes

_________________

________________

________________

______________________________________

_________________

________________

________________

______________________________________
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_________________

________________

________________

______________________________________

_________________

________________

________________

______________________________________

_________________

________________

________________

______________________________________

_________________

________________

________________

______________________________________

_________________

________________

________________

______________________________________

_________________

________________

________________

______________________________________

_________________

________________

________________

______________________________________

_________________

________________

________________

______________________________________

NOTES: _______________________________________________________________________________________________________________
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C. Appendix III: Consent Forms

Please leave enough
space at the top of your
consent form to
accommodate a box this
size.
DO NOT INCLUDE THIS
BOX

Combined Consent and Authorization to Participate in a Research Study
PLEASE NOTE: When “YOU” is referenced in the consent, it include “YOU and
YOUR BABY”
IMPACT OF IN UTERO NICOTINE EXPOSURE ON NEONATAL EX VIVO
MACROPHAGE RESPONSES

WHY ARE YOU BEING INVITED TO TAKE PART IN THIS RESEARCH?
You are being invited to take part in this research study about effects of nicotine exposure
during fetal development. You are being invited to take part in this study because you are
having a baby being delivered prematurely and we are interested in the effects of nicotine on
the formation of cells in the lungs.
WHO IS DOING THE STUDY?
The persons in charge of this study are Drs. Hubert Ballard and David Feola of the University of
Kentucky, Department of Pediatrics – Division of Neonatology and Department of Pharmacy
Practice and Science. There may be other people on the research team assisting at different
times during the study.
WHAT IS THE PURPOSE OF THIS STUDY?
By doing this study, we hope to learn how nicotine exposure during pregnancy, either from
smoking tobacco or using nicotine replacement products, will affect the development of your
baby’s ability to fight infection.
ARE THERE REASONS WHY YOU SHOULD NOT TAKE PART IN THIS STUDY?
Study personnel will make sure that you are eligible for this study. You should not participate if
you know or have been informed that you and your baby have any conditions that can affect
the immune system. Also if you take any medications chronically that can affect you and your
baby’s immune system, you may not be eligible to participate in the study.
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WHERE IS THE STUDY GOING TO TAKE PLACE AND HOW LONG WILL IT LAST?
The research procedures will be conducted at UK Medical Center, and tracheal aspirate
samples will be transferred to the laboratory of Dr. Feola for further analyses. There will be no
additional clinic visits or hospital stay due to participation in the study. Cells will be obtained
during the first 2 weeks after delivery.
WHAT WILL YOU BE ASKED TO DO?
If you wish to take part in the study, you will be provided with detailed information regarding the
study before signing the consent and permission forms. You will also be given a series of
questions to assess your smoking history. Your smoking history will be used to put you into one
of three group, which are 1) smoking group, 2) nicotine replacement group, 3) control group, or
non-smoking group. No blood sample will be collected for the sole purpose of this study. You will
receive usual hospital care as necessary and there will be no additional testing or hospital visits
after discharge. Upon delivery, your baby will also receive usual hospital care in the intensive
care unit. In order to make sure breathing tubes are not clogged, nurses usually clear out the
tube by suctioning out the secretions (which are mostly mucous and some cells) and discard
them. For this study, we will collect these samples and keep for research purposes. No
additional procedures will be done to you or your baby at any time.
We will take suctioned secretions to the laboratory and test to see their responses and any
changes in their genes. This genetic testing will not be a part of your permanent medical
record and will not involve testing your genetic makeup, only the level at which certain genes
are turned on/off. You will not be given the results of these genetic tests.
We will also look at your medical records for information regarding your general health,
smoking history, and recent labs you have had.
WHAT ARE THE POSSIBLE RISKS AND DISCOMFORTS?
You and your baby will not undergo any interventions that are not part of the usual care during
hospitalization. Therefore, there will be minimum risk to participating in the study and this will
be no more than what may be posed by the usual perinatal care at the hospital.
WILL YOU BENEFIT FROM TAKING PART IN THIS STUDY?
You will get no direct benefit for being in the study. Your willingness to take part, however, may,
in the future, help doctors better understand about nicotine exposure during pregnancy and
make proper recommendation to pregnant smokers for the health of themselves and their
babies.
DO YOU HAVE TO TAKE PART IN THE STUDY?
If you decide to take part in the study, it should be because you really want to volunteer. You will
not lose any benefits or rights you would normally have if you choose not to volunteer. You can
stop at any time during the study and still keep the benefits and rights you had before
volunteering. If you decide not to take part in this study, your decision will have no effect on the
quality of medical care you receive.
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IF YOU DON’T WANT TO TAKE PART IN THE STUDY, ARE THERE OTHER CHOICES?
If you do not want to be in the study, there are no other choices except not to take part in the study.
WHAT WILL IT COST YOU TO PARTICIPATE?
There will be no additional cost to participating in the study. Investigators will pay for laboratory
measures performed outside of what is normally reported but they will not be paying for your
hospitalization and other medical cares as these will be part of usual cares provided.
WHO WILL SEE THE INFORMATION THAT YOU GIVE?
We will make every effort to keep confidential all research records that identify you to the extent
allowed by law.
Your information will be combined with information from other people taking part in the study.
When we write about the study to share it with other researchers, we will write about the
combined information we have gathered. You will not be personally identified in these written
materials. We may publish the results of this study; however, we will keep your name and other
identifying information private.
We will make every effort to prevent anyone who is not on the research team from knowing that
you gave us information, or what that information is. Information will be secured in a locked
cabinet in a private office that has limited access. Electronic records can only be accessed
using passwords.
CAN YOUR TAKING PART IN THE STUDY END EARLY?
If you decide to take part in the study you still have the right to decide at any time that you no
longer want to continue. You will not be treated differently if you decide to stop taking part in
the study.
ARE YOU PARTICIPATING OR CAN YOU PARTICIPATE IN ANOTHER RESEARCH
STUDY AT THE SAME TIME AS PARTICIPATING IN THIS ONE?
You may not take part in this study if you are currently involved in another research study that
requires administration of certain medications chronically. It is important to let the
investigator/your doctor know if you are in another research study. You should also discuss
with the investigator before you agree to participate in another research study while you are
enrolled in this study.
WHAT HAPPENS IF YOU GET HURT OR SICK DURING THE STUDY?
If you believe you are hurt or if you get sick because of something that is due to the study, you
should call Dr. Feola at 859-323-8751 or Dr. Ballard at 859-323-5481 immediately.
It is important for you to understand that the University of Kentucky does not have funds set
aside to pay for the cost of any care or treatment that might be necessary because you get
hurt or sick while taking part in this study. Also, the University of Kentucky will not pay for any
wages you may lose if you are harmed by this study.
The medical costs related to your care and treatment because of research related harm will be
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paid by the investigators for medical expenses incurred by treating injuries that directly result
from participating in the study, with some exceptions. The exceptions are instances such as
your failure to follow the sponsor’s directions or the investigator’s failure to follow the
sponsor’s directions;
WILL YOU RECEIVE ANY REWARDS FOR TAKING PART IN THIS STUDY?
You will not receive any rewards or payment for taking part in the study.
WHAT IF YOU HAVE QUESTIONS, SUGGESTIONS, CONCERNS, OR COMPLAINTS?
Before you decide whether to accept this invitation to take part in the study, please ask any
questions that might come to mind now. Later, if you have questions, suggestions, concerns,
or complaints about the study, you can contact the investigator, Dr. Dave Feola at 859-3238751. If you have any questions about your rights as a volunteer in this research, contact the
staff in the Office of Research Integrity at the University of Kentucky between the business
hours of 8am and 5pm EST, Mon-Fri at 859-257-9428 or toll free at 1-866-400-9428. We will
give you a signed copy of this consent form to take with you.
WHAT IF NEW INFORMATION IS LEARNED DURING THE STUDY THAT MIGHT AFFECT
YOUR DECISION TO PARTICIPATE?
If the researcher learns of new information in regards to this study, and it might change your
willingness to stay in this study, the information will be provided to you. You may be asked to
sign a new informed consent form if the information is provided to you after you have joined
the study.
WHAT ELSE DO YOU NEED TO KNOW?
There is a possibility that the data/tissue/specimens/blood collected from you may be shared
with other investigators in the future. If that is the case the data/tissue/specimen/blood will not
contain information that can identify you unless you give your consent/authorization or the UK
Institutional Review Board (IRB) approves the research. The IRB is a committee that reviews
ethical issues, according to federal, state and local regulations on research with human
subjects, to make sure the study complies with these before approval of a research study is
issued.
AUTHORIZATION TO USE OR DISCLOSE YOUR IDENTIFIABLE HEALTH INFORMATION
The privacy law, HIPAA (Health Insurance Portability and Accountability Act), requires
researchers to protect your health information. The following sections of the form describe how
researchers may use your health information.
Your health information that may be accessed, used and/or released includes:

•

Age, medical history, smoking history, family history, and your babies gestational age

The Researchers may use and share your health information with:
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•
•
•

The University of Kentucky’s Institutional Review Board/Office of Research Integrity.
Law enforcement agencies when required by law.
University of Kentucky representatives.

The researchers agree to only share your health information with the people listed in this
document.
Should your health information be released to anyone that is not regulated by the privacy law,
your health information may be shared with others without your permission; however, the use of
your health information would still be regulated by applicable federal and state laws.
You may not be allowed to participate in the research study. If you decide not to sign the form,
it will not affect your:
•
•
•
•

Current or future healthcare at the University of Kentucky
Current or future payments to the University of Kentucky
Ability to enroll in any health plans (if applicable)
Eligibility for benefits (if applicable)

After signing the form, you can change your mind and NOT let the researcher(s) collect
or release your health information (revoke the Authorization). If you revoke the
authorization:

•
•
•

You will send a written letter to: Dave Feola to inform him of your decision.
Researchers may use and release your health information already collected for this
research study.
Your protected health information may still be used and released should you
have a bad reaction (adverse event).

The use and sharing of your information has no time limit.
If you have not already received a copy of the Privacy Notice, you may request one. If
you have any questions about your privacy rights, you should contact the University of
Kentucky’s Privacy Officer between the business hours of 8am and 5pm EST, Mon-Fri
at: (859) 323-1184.
You are the subject or are authorized to act on behalf of the subject. You have read this
information, and you will receive a copy of this form after it is signed.
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_
Signature of research subject (if applicable:)

Date

or *research subject’s legal representative
_______________________
Printed name of research subject (if applicable:)
or*research subject’s legal representative

Relation to
research subject

*(If, applicable) Please explain Representative’s relationship to subject and include a
description of Representative’s authority to act on behalf of subject:
_

_

_

_

_

_

_
_
Name of [authorized] person obtaining informed consent/HIPAA authorization

_
_
Signature of Principal Investigator or
Sub/Co-Investigator
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_______
Date

D. Appendix IV: Impact of In utero Nicotine Exposure on Neonatal Ex vivo
Macrophage Responses Study IRB Research Description

1.

Background:
Smoking during pregnancy is associated with adverse perinatal outcomes,
including miscarriage, prematurity, low birth weight, and neonatal or sudden
infant death. Numbers of studies show an increase in respiratory symptoms
and altered immune defense in infants and children exposed to maternal
smoking during pregnancy (1-3). Although smoking is a preventable risk
factor of pregnancy related morbidity and mortality, >10% of pregnant women
in high-income countries smoke during pregnancy and the rates are
increasing in low- and middle-income countries (3, 4). Medications, including
nicotine replacement therapy (NRT), have been developed and approved by
the FDA to assist smoking cessation but there is a paucity of data regarding
the safety and effectiveness of therapy during pregnancy and its effects on
fetal development. Yet there is a general consensus internationally that
recommends the use of NRT during pregnancy, assuming that nicotine
replacement will reduce the symptoms of craving and withdrawal while
reducing the exposure of toxins from cigarette smoke (3, 4). A recent study on
the use of NRT patches during pregnancy until delivery found that there is no
difference in the rate of abstinence from smoking or the risk of adverse
perinatal outcomes compared to placebo, although the rate of abstinence was
higher at 1 month of therapy in the NRT group (4). There are various factors
that could lead to the observed outcomes, and conclusions from the study
should be derived with careful interpretation since compliance rate in both
groups were very low (< 10%).
Nicotine, one of the main components of tobacco and a pharmacologically
active compound in NRT, is an agonist for nicotinic acetylcholine receptor
(nAChR). nAChR are mainly found in the central and peripheral nervous
systems. The expression of these receptors are also found in non-neuronal
cells, modulating various cellular functions such as proliferation,
differentiation, and migration via paracrine/autocrine fashion (6, 7). In immune
cells, functional alteration of macrophages upon stimulation with nicotine or
modulation of nAChR are well documented. Previous studies show that
nicotine exposure drives macrophages into an alternative M2 phenotype,
suggested by the characteristics of surface markers and cytokine production
profile (8, 9). Macrophages that were polarized into classical M1 phenotype
and alternative M2 phenotype in the presence and absence of nicotine
showed that nicotine exposed M1 polarized macrophages (Ni-M1)
demonstrated surface marker expressions similar to those seen in M2
polarized macrophages. Upon stimulation with LPS, cytokines produced by
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Ni-M1 were different from M1 polarized macrophages, suggested by a
significantly lower IL-12 production. Although cytokine profile of Ni-M1 did not
result in the same profile seen in M2 polarized macrophages, the
investigators reported skewed macrophage differentiation towards M2
phenotype with nicotine exposure (9).
While it is meaningful to understand the alteration of immune cells upon
nicotine exposure, it is significant to understand the impact of this alteration
as a defense mechanism. In vitro model of alveolar macrophages (AM)
infected with Legionella pneumophila shows changes in antimicrobial activity
and cytokine production of AM upon treatment with nicotine (10). This effect
was reversed by nAChR antagonist treatment. In this study, enhanced growth
of L. pneumophila in nicotine treated macrophages was observed, which was
associated with reduction in production of cytokines IL-6, IL-12, and TNF-α by
AM. Nicotine did not contribute to direct antimicrobial activity, suggesting that
nicotine probably decreases phagocytic activities of AM.
Recently, the effects of in utero nicotine exposure on neonatal mice AM
were evaluated. Both in vitro and in vivo studies demonstrated markers of AM
shifted into M2 phenotype, characterized by increases in arginase-1, YM1,
and FN. These alterations contribute to the baseline profile of neonatal lung
characterization into Th2 immune response, which is further supported by an
increased IL-13 and TGFβ1 expression. This study also demonstrated
impaired phagocytic activity by in utero nicotine exposed AM upon
Staphylococcus aureus infection. Using α7 nAChR knockout model, the
involvement of such receptor subunit in immunomodulatory effects of nicotine
was observed, which is consistent with previous studies (8). This model
demonstrates possible effects of NRT on the development of fetal immune
system and the inflammatory “tone” of neonatal AM set at birth.
Our preliminary findings with mice exposed to nicotine developmentally
suggested that these mice have greater morbidity and increased inflammatory
cytokine production upon Pseudomonas aeruginosa lung infection compared to
those not exposed to nicotine developmentally. Taken all together, the effect of
nicotine from NRT on fetal immune development and thus neonatal immune
response signifies the importance of investigating the immune function of pulmonary
macrophages during the neonatal period, especially without strong evidence of the
effectiveness and safety of in utero nicotine exposure via NRT use in pregnant
mothers
2.

Objectives: This study is designed to observe the effects of developmental
nicotine exposure, either from tobacco smoking or from nicotine replacement
therapy, on neonatal alveolar macrophage characteristics obtained from
tracheal aspirate (TA) samples.

3.

Study Design: This study will be a prospective, single-center, observational
investigation. There will be no study medications administered by the
investigators. Participants will be grouped into three different arms, Smoking
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group vs. Replacement group vs. Control, based on their smoking status
during pregnancy.
4.

Study Population: Mothers aged 18-50 years old whose newborns are
placed on a ventilator in the Neonatal Intensive Care Unit (NICU) will be
contacted for potential enrollment of their babies in the study. There will be
three different groups with 10 participants in each group: 1) smoking group
vs. 2) nicotine replacement group vs. 3) control group. Use of 5 or more
cigarettes daily during pregnancy will be required to be enrolled in the
smoking group while use of nicotine replacement products (patch, gum,
inhaler, nasal spray, lozenges) during pregnancy and continued abstinence
will be required for their infants to be enrolled in the replacement group.
Control group will be defined by no exposure to nicotine during pregnancy.
Although best efforts will be made to include participants whose mothers have
smoked consistently throughout pregnancy, it is reasonable that some
pregnant smokers may only smoke periodically. As long as there was no
record of using NRT at any point during pregnancy, these participants will be
enrolled in the smoking group. Similarly, smokers using NRT will often-times
relapse. Based on smoking history obtained, investigators will make a
decision whether to include their infants in the replacement group and such
data will be handled statistically. Participants will be excluded if there is
known major fetal abnormalities, chemical/alcohol dependence,
contraindication to NRT, use of any forms of tobacco other than cigarettes
and e-cigarettes, and any active infection, both mother and the newborn, at
the time of delivery, before sample collection. Premature infants requiring
mechanical ventilation for reasons other than assisting “physiologic normalcy”
will be excluded from the study as well. Mothers taking any chronic
medications known to pose immunomodulation, such as steroid, or have
potential for causing immunomodulation will also be excluded from the study.
Since this study is designed to observe the effects of developmental nicotine
exposure on alveolar macrophage characteristics of neonates, inclusion of
newborns are crucial.

5.

Subject Recruitment Methods and Privacy: Participants will be identified by
hospital number and date of birth. Initial contact with potential participants will
be made after the delivery and they will be inquired about their interest in
participating in the study. Detailed information about the study and its
objectives will be provided by the study investigator, and signed informed
consents and parental permission form will be obtained before enrollment. A
series of questions will be asked to accurately determine the number of
cigarettes smokes, time of the last cigarette smoked or the time of initiation of
nicotine replacement therapy and the last NRT product used to enroll
participants to corresponding study group.

6.

Informed Consent Process: Informed consent and parental permission form
to include babies in the study will be provided at recruitment and signed
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informed consent will be required prior to participant enrollment. This will be
collected by the study investigators to make sure participants fully understand
the purpose and procedures involved in the study and to answer any
questions. Upon the receipt of the signed consent form, record of such action
will immediately be documented electronically and maintained throughout
study period.
7.

Research Procedures: All participants will undergo initial screening process
for inclusion/exclusion criteria on the day of recruitment. Signed informed
consent and parental permission form by the potential participant will be
required to be enrolled in the study. Baseline data (date of birth, hospital
number, ethnicity, medical history, daily number of cigarettes smoked during
pregnancy, time from last cigarette smoked/nicotine replacement product use,
partner’s smoking status, gestational age, signed consent form, a list of
acute/chronic medications, medications administered during current
hospitalization, and indication of participant’s contact details) will be collected
through a series of questionnaires as well as from the subject’s medical
record (see attached data collection tools). For TA collection: TA suctioning
is performed as part of routine care in the neonatal intensive care unit and
these specimens are discarded thereafter. For the purpose of this study, 0.5
to 1 mL of suctioned specimens will be collected within the first week of birth
for 2-3 samples per baby (up to 5 samples) or less if extubated earlier.
Specimens will be collected in pre-labeled tubes on ice and immediately
transported to the laboratory of Dr. Feola.
For TA samples: specimen will be centrifuged to pellet the cells, then cells
will be washed 3 times with RPMI media and counted using a
hemocytometer. Cells will be seeded at 1-2x105 cells per well in 24-well
plates, removing non-adherent cells after 1-2 hours, leaving macrophages
intact. Lipopolyssacharide (LPS) from Escherichia coli O55:B5 from EMD
Millipore will be used to stimulate inflammatory responses. mRNA from cells
will be isolated and purified using the Qiagen RNeasy Kit (Qiagen Sciences,
Germantown, MD). mRNA concentration and sample purity will be calculated
by measuring ultraviolet absorbance at 230, 260, and 280 nm using a
spectrophotometer. Samples will be frozen at -80̊C for microarray analysis.
Microarrays will be performed on mRNA samples using the TaqMan®
Gene Expression Array Plates (Applied Biosystems, Foster City, CA).
TaqMan® arrays are flexible, affordable, and convenient for gene expression
analysis screening for specific biological pathways, processes, diseases, or
can be customized. These arrays each consist of 48 genes of interest, such
as TNFa, IL-1, IL-10, and CD86. RNA samples (0.1-10ug) will be converted
into cDNA, and using 10-100 ng of cDNA per plate, Applied Biosystems realtime quantitative PCR instrument will allow amplification of target genes.
Gene expression can be measured by the quantitation of cDNA relative to a
calibrator sample, which serves as a physiological reference. All quantitations
will be also normalized to an endogenous control to account for variability in
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the initial concentration and quality of the total RNA and in the conversion
efficiency of the reverse transcription reaction.
Additionally, cytokine concentrations from cell culture supernatant will be
quantified using BDTM Cytometric Bead Array (CBA Kits (BD Biosciences,
San Jose, CA). Bead populations distinct fluorescence intensities are coated
with capture antibodies specific for each cytokine to be measured. These
beads will be incubated with fluorochrome-conjugated detection antibodies,
and then incubated with 50uL of each sample for 3 hours at room
temperature. Sandwich complexes are then formed, after which the beads are
washed, and the fluorescence intensity is assayed by flow cytometry. These
intensities are then compared to a standard curve generated for each
cytokine to determine the concentration in each sample.
Gene and protein expression levels in TA will be statistically analyzed
through principal component analyses. These expression levels will then be
compared among groups and correlated to clinical outcomes (demographic
information, smoking status, gestational age, etc.) acquired through
retrospective review of the chart.
8.

Resources: This will be a single center study, performed at the University of
Kentucky Medical Center. In addition to the investigators listed, nurses who
routinely work in the neonatal intensive care unit under the medical direction
of neonatologist Dr. Hubert Ballard will assist in collection of TA sample. Upon
sample collection, this will be transported to the laboratory of David Feola at
the Department of Pharmacy Practice and Science at University of Kentucky
for further analysis.
Dr. Feola’s research laboratory space at the College of Pharmacy will be
utilized. The PI operates wet-lab functions in approximately 1000 ft2 of space.
The lab employs the use of Class II biosafety cabinets and is approved for
biosafety level 2 works through the Institutional Biosafety Committee. This
lab also contains all needed equipment to conduct this research, including
refrigerators, freezers, incubators, centrifuges, and microscopes.

9.

Potential Risks: Potential risks to the patient from this study are minimal and
include unanticipated breaches of confidentiality, in which case the IRB will be
notified immediately. No invasive procedure will be performed on patients
enrolled in this study for the sole purpose of the study, and TA specimens,
which will be suctioned out and discarded as a routine care, will be collected
for the study. There will be no study drug administered to participants in this
study. Strict adherence to confidentiality requirements will ensure the patients’
data and demographic information is protected.

10.

Safety Precautions: In order to minimize the risks of breaching
confidentiality or invasion of privacy, paper documents that contain patient
information will be stored in a locked cabinet in room 231 of BioPharm
Complex and any electronic data will be made accessible with password. All
standard perinatal care will be provided to participants, and their enrollment in
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the study will not prevent them from receiving any additional interventions
necessary for unanticipated problems during hospitalization. If mothers raise
any concerns or questions about the procedures for themselves as well as
the newborns, they are able to withdraw from the study at any point after
enrollment.
11.

Benefit vs. Risk: Samples collected from this study will be obtained as a part
of routine standard measures and there is minimum risk to participants. No
blood will be drawn for the sole purpose of this study. TA suctioning is
performed as part of routine care in the neonatal intensive care unit, and
these specimens will be stored and transferred to Dr. Feola’s laboratory for
analysis.

12.

Available Alternative Treatment(s): There will be no study drug
administered/provided by the investigators and the sources of samples
obtained during the study will be part of standard care.

13.

Research Materials, Records, and Privacy: Baseline data (please refer to
#7) from mothers and newborns, and TA samples from newborns will be
collected. They will be individually labeled with corresponding participant’s
hospital number followed by the type of sample and the date of collection. TA
samples will be collected as described above and processed immediately. All
data outline above, including chart information, smoking status, immune
system genetic profile, cytokine concentration will be recorded electronically
and will be made accessible with password and secured in a locked office
(231 College of Pharmacy).

14.

Confidentiality: Baseline data collected from the participants will be saved in
a locked cabinet in room 231 of BioPharm Complex, accessible to only the
research investigators. Any information obtained electronically will require
password-protected access. Upon collection of specimen, they will be initially
stored in a limited access environment and will be transported immediately to
the laboratory of Dr. Feola for storage/analysis, at which de-identification will
occur by re-assigning sample number to a unique identifier code consisting of
a number to designate each participant followed by letters to designate
sequence of samples collected from that individual. This will be recorded
electronically and access will require password. Patient data and specimens
will be stored for perpetual maintenance for the accuracy of results
interpretation.

15.

Payment: Not applicable. There are no incentives or payments for
participation in this study.

16.

Costs to Subjects: There will be no costs that are the participant’s
responsibility as a consequence of participating in the research. All costs
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associated with the procedure beyond the usual standard of care procedures
will be directed to the research investigators.
17.

Data and Safety Monitoring: This study has a minimal risk to the
participants as all the procedures involved in obtaining patient information and
samples are part of usual standard of care measures and will be under the
medical direction of Dr. Ballard. Therefore, no monitoring is required.

18. Subject Complaints: Participants will be able to raise any concerns or
questions regarding the study and study procedures at any point, and study
investigators will make best efforts to meet with them face-to-face to clarify
and address their concerns. Additionally, they will be able to withdraw from
the study at any point, and the use of collected data for analysis will be
discussed.
19. Research Involving Non-English Speaking Subjects or Subjects from a
Foreign Culture: Mothers who cannot speak and understand English will not
be enrolled in the study. Very few Hispanic mothers smoke, therefore it will
not significantly decrease potential pool of subjects
20. HIV/AIDS Research: Not applicable
21. PI-Sponsored FDA-Regulated Research: Not applicable
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